Of mice and men: molecular genetics of congenital heart disease

Troels Askhøj Andersen · Karin de Linde Lind Troelsen · Lars Allan Larsen

Received: 3 June 2013 / Revised: 16 July 2013 / Accepted: 18 July 2013 / Published online: 10 August 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract Congenital heart disease (CHD) affects nearly 1 % of the population. It is a complex disease, which may be caused by multiple genetic and environmental factors. Studies in human genetics have led to the identification of more than 50 human genes, involved in isolated CHD or genetic syndromes, where CHD is part of the phenotype. Furthermore, mapping of genomic copy number variants and exome sequencing of CHD patients have led to the identification of a large number of candidate disease genes. Experiments in animal models, particularly in mice, have been used to verify human disease genes and to gain further insight into the molecular pathology behind CHD. The picture emerging from these studies suggest that genetic lesions associated with CHD affect a broad range of cellular signaling components, from ligands and receptors, across downstream effector molecules to transcription factors and co-factors, including chromatin modifiers.

Keywords Congenital heart disease · CHD · Disease genes · Copy number variants · CNVs

Introduction

Congenital heart disease (CHD) is the most prevalent birth defect, with a postnatal incidence of 0.8 % [1] and an approximately tenfold higher prenatal incidence [2]. CHD is a group of structural abnormalities of the heart, which include septal defects, valve defects and lesions affecting the outflow tract. The treatment of CHD has improved during the last 50 years, and today 95 % of CHD patients survive to adulthood, which has resulted in a growing population of adults living with CHD [3].

The etiology of CHD is complex and is associated with both environmental and genetic causes. Genetically, CHD is a very heterogeneous disease; 55 human disease genes have been identified so far (Table 1 and text below), however, experiments with targeted deletions in mice have revealed more than 500 genes which lead to heart defects when mutated (http://www.informatics.jax.org/). Thus it is likely that at least the same number of human CHD disease genes exist.

During the last two decades, linkage analysis has been used to successfully identify CHD disease genes in large families, segregating isolated CHD and genetic syndromes, where CHD is part of the phenotypic spectrum (syndromic CHD). Furthermore, fine-mapping of genomic copy number variants (CNVs) in patients with isolated CHD, or CHD in combination with additional birth defects, have been used to identify candidate disease genes. Follow-up studies of candidate genes in animal models, particularly in mice, have been very successful in validating the candidates, and to gain insight into the function of the gene products in heart development.

Identifying disease genes in CHD is critically important to understand the disease. Identification of a novel disease gene or a causative pathway will enhance current knowledge of the molecular biology involved in human cardiac development, and the molecular pathology underlying CHD. Such knowledge may lead to new preventive strategies and perhaps new treatments. Furthermore, such knowledge may also increase our understanding of the factors involved in cardiomyogenic stem cell differentiation, and may thus aid in the development of regenerative...
Table 1  Genes associated with CHD via intragenic mutations

| HCNG gene symbol (alternative symbol) | Protein functiona | Type of CHDb | Reference |
|--------------------------------------|-------------------|--------------|-----------|
| **Genes encoding transcription factors** |                   |              |           |
| CITED2                               | Transcriptional co-activator | I           | [18]      |
| FOXH1                                | Forkhead box TF    | I            | [29]      |
| FOXP1                                | Forkhead box TF    | I            | [246]     |
| GATA4                                | GATA-binding TF    | I            | [89–91]   |
| GATA6                                | GATA-binding TF    | I            | [247, 248]|          |
| IRX4                                 | Iroquois homeobox TF | I          | [249]     |
| MED13L                               | Multrotein coactivator subunit | I          | [250]     |
| NKX2-5                               | Homeobox TF        | I            | [69–71]   |
| NKX2-6                               | Homeobox TF        | I            | [251]     |
| TBX1                                 | T-box TF           | S (DiGeorge syndrome) | [156] |
| TBX5                                 | T-box TF           | S (Holt–Oram syndrome) | [102, 103] |
| TBX20                                | T-box TF           | I            | [104]     |
| SALL4                                | Zinc finger TF     | I, S (Duane-radial ray syndrome) | [252–255] |
| TTBAP2B                              | AP-2 TF            | I, S (Char syndrome) | [110–112] |
| ZFPM1                                | Zinc finger TF     | I            | [255, 256]|          |
| ZIC3                                 | Zinc finger TF     | HTX          | [19]      |
| **Genes involved in cell signaling** |                   |              |           |
| ACRV1                                | Activin receptor, type 1 | I          | [257]     |
| ACRV2B                               | Activin receptor 2B | HTX         | [14]      |
| BRAF                                 | Serine/threonine protein kinase | S (NS, LS, CFC) | [56, 64] |
| CBL                                  | E3 ubiquitin ligase | S (NS-like) | [66]      |
| CFC1                                 | Ligand (EGF family) | HTX         | [17]      |
| GDF1                                 | Ligand (BMP/TGFbeta family) | HTX | [16]   |
| HRA5                                 | RAS GTPase         | S (Costello syndrome) | [63] |
| JAG1                                 | NOTCH ligand       | S (Alagille syndrome) | [37, 38]|          |
| LEFTY2 (LEFTYA)                      | Ligand (BMP/TGFbeta family) | HTX | [14]   |
| KRAS                                 | RAS GTPase         | S (NS, CFC) | [56, 57]|          |
| MAP2K1 (MEK1)                        | MAP kinase kinase  | S (CFC)     | [64]      |
| MAP2K2 (MEK2)                        | MAP kinase kinase  | S (CFC)     | [64]      |
| NF1                                  | Negative regulator of RAS-MAPK signalling | S (neurofibromatosis-NS) | [67] |
| NRAS                                 | RAS GTPase         | S (NS)      | [62]      |
| NODAL                                | Ligand (BMP/TGFbeta family) | HTX | [12, 13] |
| NOTCH1                               | NOTCH receptor     | I           | [45–47]   |
| NOTCH2                               | NOTCH receptor     | S (Alagille syndrome) | [41, 42]|          |
| PFGFR1                               | PFGFRa receptor    | I           | [258]     |
| PTPN11                               | Protein tyrosine phosphatase | S (NS) | [55]   |
| RAF1                                 | MAP kinase kinase  | S (NS, LS)  | [60, 61]|          |
| RIT1                                 | Ras-related GTPase | S (NS)      | [259]     |
| SHOC2                                | RAS-MAPK modulator | S (NS)      | [65]      |
| SMAD6                                | BMP/TGFbeta modulator | I         | [260]     |
| SOSI                                 | Guanine nucleotide exchange factor (RAS-MAPK pathway) | S (NS) | [58, 59]|          |
| TAB2                                 | Activator of MAP3K7 (TAK1) | I          | [236]     |
| TDGF1                                | Co-receptor for TGF-β ligands | I       | [29]      |
| **Genes encoding structural proteins** |                   |              |           |
| ACTC1                                | Cardiac α-actinin  | I            | [124]     |
| EAN                                   | Elastin            | f            | [184]     |

a Protein function is based on the gene's known role in transcriptional regulation or signaling pathways.
b Type of CHD refers to the specific type of congenital heart defect associated with the gene variant.

References...
therapy for treatment of myocardial infarction. In familial cases of CHD, identification of disease genes will benefit the genetic counseling process for CHD-afflicted families. Such knowledge is particularly important for the growing population of adults with CHD, due to the high recurrence risk of certain forms of CHD [4].

In this review, we aim to summarize current knowledge in the molecular genetics of CHD, from the perspective of, disease gene identification efforts in humans, and functional analyses of disease genes in animal models.

### Part I: genes associated with congenital heart disease

Below we discuss genes associated with syndromic and isolated CHD, juxtaposing studies from multiple model systems to clarify why errors in the underlying molecular machinery manifests themselves as congenital heart defects.

#### Genes associated with laterality defects

The heart is the first organ to break the bilateral symmetry of the developing embryo. During early embryogenesis, left–right asymmetry of the body-axis is established via intricate cross-talk amongst signaling pathways such as Notch, Nodal, Hedgehog, FGF and BMP, ultimately restricting NODAL signaling to the left side of the embryo. The nodal cilia model is the predominant model to elucidate induction of embryonic asymmetry in the developing embryo, although other models have been proposed [5]. Briefly, nodal cilia in the node of the primitive streak produce a directional fluid flow which induces left–right asymmetry by delivering morphogens to the left side of the embryo and/or by acting on mechanosensory cilia [6–9]. Ultimately, laterality cues are relayed downstream to ensure left-sided expression of the PITX2 transcription factor in the lateral plate mesoderm [10], a critical component in determining organ laterality [11].

*CHD7* [12, 13], *LEFTY2* [14], *ACVR2B* [15], *GDF1* [16] *CFC1* [17], *CITED2* [18] and *ZIC3* [19] have all been localized to the laterality signaling pathway. Albeit human mutations in these genes show a wide range of heart malfunctions, many cluster around laterality defects such as heterotaxy and faulty looping of the heart. Interestingly, a recent study identified mutations in *Nephronophthisis-4* (*NPHP4*), a cilia related gene, and linked them to a variety of cardiac laterality defects such as transposition of the great arteries (TGA), atrioventricular septal defects (AVSD), double outlet right ventricle (DORV), dextrocardia and abnormal pulmonary venous return. Laterality defects of the abdominal organs were also observed. Morpholino knock down of *nphp4* in zebrafish resulted in reverse orientation or faulty looping of the heart [20]. Previous studies have also connected other NPHP family members to inborn heart defects and laterality deficiencies [21, 22].

The *ZIC3* gene encodes a zinc finger transcription factor known to cause cardiovascular defects when mutated...
in humans. Mutations in ZIC3 cause X-linked familial heterotaxy but are also found in sporadic cases of heterotaxy and isolated CHDs [19, 23, 24]. Null and heterozygous Zic3 mice display a variety of cardiac defects such as TGA, interrupted aortic arch (IAA), atrial septum defect (ASD) and ventricular septal defect (VSD) in combination with various other developmental anomalies, thus resulting in a phenocopy of the clinical spectrum of malfunctions found in humans with heterotaxy [25]. How mutations in ZIC3 result in faulty heart looping is currently unknown. However, recent reports place ZIC3 upstream in the Nodal signal cascade [25, 26] with conditional loss-of-function studies showing that ZIC3 is required in the migrating mesoderm but not for heart progenitors and in the heart compartment [27].

Recently, the transcription factor FOXH1 was outlined as a possible signaling intersection between BMP and Nodal signaling to establish left/right asymmetry [28]. Mutations in FOXH1 have been linked to human heart defects [29], as well as the lack of outflow tract and right ventricle is seen in Foxh1−/− mouse embryos [30].

In humans, mutations in the transcriptional co-activator CITED2 (Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain 2) are associated with laterality defects and cardiac anomalies such as septal defects and TGA [18]. Mice deficient in Cited2 die during gestation expressing partially penetrant laterality defects and fully penetrant heart defects [31, 32]. The heart anomalies include ASD, VSD, common atrioventricular canal (CAvC), DORV and IAA type B [32, 33]. Recently, Lopes et al. [31] showed that specific deletions of Cited2 in heart progenitors do not produce heart defects and that the cardiac malfunctions seen in Cited2−/− embryos arise during the early phases of establishing the left–right body axis in close relation to NODAL signaling.

Genes encoding components of signaling pathways

Animal models have illustrated that cardiac development involves spatial and temporal coordination of a number of signaling pathways [34, 35]. The identification of disease genes in syndromic and isolated CHD has confirmed the involvement of a subgroup of these pathways in human heart development, and has further contributed new information about additional pathways.

The NOTCH signaling pathway acts locally as a cell-fate regulator, and as a patterning signal effector in many developmental processes. Its activity includes left–right axis partitioning and heart morphogenesis. For an extensive review on Notch signaling in cardiac development see [36].

Identification of mutations in JAG1, encoding a NOTCH signaling ligand, in patients with Alagille syndrome provided the first link between NOTCH signaling and human CHD [37, 38]. Alagille syndrome (AGS, OMIM #118450) is a multisystem disorder, which involves the liver, heart, eyes, face and skeleton [39]. Approximately 90 % of these patients have cardiovascular anomalies, often presenting in the form of stenosis in the pulmonary artery branch, valvular pulmonary stenosis (PS) and tetralogy of Fallot (TOF) [40]. The majority (>90 %) of AGS cases are caused by mutations in JAG1, however select (<1 %) cases are caused by mutation in NOTCH2 [41, 42]. Mice homozygous for targeted deletion of Jag1 die during embryonic development possibly due to vascular defects while heterozygous Jag1+/− mice display ocular defects [43].

In contrast, doubly heterozygous Jag1+/−, Notch2+/− mice exhibit multiorgan abnormalities characteristic of AGS, supporting a genetic interaction between JAG1 and NOTCH2 in AGS [44].

Mutations in NOTCH1 have been identified in patients with isolated CHD [45–47]. Patients with NOTCH1 mutations often present malfunctions of the aortic valve. NOTCH1 signaling has been linked to endothelial-to-mesenchymal transformation (EMT), a fundamental process in the early stages of cardiac valve formation, where endocardial cells detach to become a migratory mesenchyme that forms endocardial cushions, precursors of cardiac valves. Notch1 mutant mice develop hypoplastic endocardial cushions due to impaired EMT [48]. Recently, Luna-Zurita et al. and others [48–50] outlined that a NOTCH1, WNT4 and BMP2 signal interplay between the endocardium and myocardium underlie valve morphogenesis. Furthermore, Bosse et al. [51] showed that compound mutant Notch+/−; Nos3−/− mice display an accelerated bicuspid aortic valve phenotype compared to Notch+/− and Nos3−/− alone, suggesting an interaction between nitric oxide (NO) and NOTCH signaling in the development of the aortic valve. In the same paper, these data were further supported by in vitro data, suggesting that NO regulates Notch signaling in aortic valve interstitial cells.

Signal transduction through the RAS-mitogen activated protein kinase (MAPK) pathway can stimulate cell proliferation, differentiation, survival and metabolism. Identification of disease genes in Noonan syndrome (OMIM #163950), Costello syndrome (OMIM #218040), LEOPARD syndrome (OMIM #151100), Cardio-facio-cutaneous (CFC) syndrome (OMIM #115150) and a few other syndromes with distinct but overlapping phenotypes, collectively known as RASopathies (see [52] for review), have firmly established a link between the RAS-MAPK signal transduction pathway and human CHD. The RASopathies are manifested by a wide range of multisystem anomalies, including CHD. In Noonan syndrome approximately 85 % of patients have a variety of cardiac defects, most commonly including pulmonary valve stenosis, ASD and hypertrophic cardiomyopathy [53, 54].

 Springer
Linkage analysis and mutation screening has identified mutations in PTPN11 as the cause of approximately half of cases with Noonan syndrome [55]. Subsequently, mutations in KRAS [56, 57], SOS1 [58, 59], RAF1 [60, 61], NRAS [62], Hras [63], BRAF [56, 64], SHOC2 [65], MAP2K1 (MEK1) and MAP2K2 (MEK2) [64], CBL [66] and NFI [67] have been associated with RASopathies in which CHD are observed (Table 1).

Genes encoding cardiac transcription factors

Cardiac developmental signals are conveyed to transcriptional circuits that regulate gene expression during normal heart development. At the heart of these transcriptional networks lie a set of core transcription factors many of which are associated with isolated CHD (Table 1). Transcriptional focal points include NKX2-5, GATA4 and TBX5. These transcription factors interact at cardiac promoters in synergistic fashions (see below). Their function and molecular signatures have been thoroughly described and excellently reviewed elsewhere, and will only be briefly mentioned here (see [68] for a recent review).

In humans, disease causing mutations in the homeodomain protein NKX2-5 result in a plethora of CHDs including ASD, VSD, TOF and DORV [69–71] Septal defects and atrio-ventricular conduction defects are commonly seen in patients with a mutated NKX2-5 gene [70]. Disruption of Tinman, the homologue of NKX2-5 in Drosophila melanogaster, results in a fruit fly devoid of the dorsal vessel, a structure analogous to the human heart [72]. Similarly, Nkx2-5 functionally is crucial in mice as homoygous mutations cause embryonic lethality due to faulty cardiac looping and insufficient myocardial differentiation during chamber formation [73, 74]. Mouse studies show that Nkx2-5 gene dosage is critically important for properly regulated development of the cardiac conduction system as Nkx2-5 null mice lack the primordium of the AV node and the conduction system of heterozygous mutant embryos only contain half the normal number of cells [75]. Additionally, Pashmforoush et al. [76] generated ventricular-restricted Nkx2-5 knockout mice that display progressive complete heart block and massive trabecular muscle overgrowth.

NKX2-5 ranks high in the cardiac regulatory hierarchy and is expressed in both the first- and second heart field (SHF) [77]. Its expression is closely coordinated through GATA factors, SMAD proteins and by self-autoregulation [78–81]. Proliferation of the SHF and outflow tract (OFT) morphology is regulated by Nkx2-5 feedback repression of BMP2/SMAD1 signaling [82]. It was recently shown that JARID2, which is also implicated in OFT development, is a direct target of NKX2-5 regulation [83]. Furthermore, it has been demonstrated that Nkx2-5 interacts with Gata4 within cardiac promoters, suggesting that the proteins cooperate in the transcriptional activation of cardiac target genes [84, 85]. Nkx2-5 interacts with Tbx5 in vitro and the two proteins were shown to activate a cardiac-specific Nppa promoter in a synergistic fashion [86] and Nkx2-5 cooperates with Tbx5 in development of the cardiac conduction system in vivo [87].

GATA binding protein 4 (GATA4) plays a pivotal role near the top of the transcriptional cascades that control heart development (see [88] for a recent review). In humans, the cardiac defects found in patients with interstitial deletions in 8p23.1 are attributed to haploinsufficiency of GATA4 (see below). Intragenic GATA4 mutations can also cause isolated CHDs, primarily cardiac septal defects, but PS, TOF and other defects have been reported [89–91]. In a recent paper human missense mutations in GATA4 were shown to disrupt GATA4–SMAD4 interactions in the BMP/TGF-β signaling pathway, likely causing AVSD and valve abnormalities in the affected patients [92]. Embryonic development in Gata4 deficient mice is arrested at E10.5 with incorrect ventral folding, endocardial malfunctions and an inability to establish a primitive heart tube [93, 94]. Correct Gata4 dosage is critically important for normal heart development, as mice homozygous for a hypomorphic allele develop CAVC, DORV and a hypoplastic ventricular myocardium [95]. Furthermore, it has also been shown that mice heterozygous for GATA4 mutations develop septation and endocardial cushion defects [90]. Heterozygous knock-in mice harbouring a Gata4 G296S mutation, previously identified in patients with septum defects and pulmonary valve stenosis, display ASD and semilunar valve stenosis [96].

GATA4 interacts with numerous transcription factors that promote cardiogenesis [88]. Direct downstream targets of GATA4 include HAND2 and MEF2C required for SHF development [97, 98]. GATA4 and TBX5 proteins physically interact and this interaction is disrupted by mutations in GATA4 [89]. Furthermore, Gata4 and Tbx5 double heterozygous mice develop cardiovascular defects, which point towards a genetic interaction between the two [99].

The T-box transcription factors are important cardiac transcription factors. They are involved in fundamental cardiac developmental processes, including development of the chamber myocardium, outflow tract and the conduction system [100]. TBX1 regulates proliferation of cardiac progenitors in the SHF and haploinsufficiency of TBX1 is considered the primary cause of CHD in patients with DiGeorge syndrome (see below). TBX5 participates in regulation of gene expression in the developing chamber myocardium and conduction system [101]. Mutations in TBX5 cause Holt–Oram syndrome (OMIM #142900), a syndrome distinguished by upper limb defects and heart defects—primarily septal and conduction defects [102, 103]. Tbx5 null mice possess a deformed linear heart tube.
and underdeveloped atria while heterozygous Tbx5 mice model heart and limb abnormalities observed in Holt–Oram syndrome, potentially explaining cardiac conduction system defects seen in these patients [101].

Human mutations in TBX20 cause aberrant valvulogenesis, septal defects, TOF and cardiomyopathy [104]. Deletion of Tbx20 in mice generates a linear heart tube which fails to loop properly and exhibits insufficient chamber formation [105]. Heterozygous Tbx20 mice show onset of dilated cardiomyopathy recapitulating some of the human defects [106]. Recent papers by Cai and co-workers [107, 108] place TxB20 in the formation of the cardiac atrio-ventricular canal in a complex signaling network involving TBX20, TBX2 and BMP2.

In vitro, transcription factor AP-2gamma (TFAP2C) has been shown to bind the TBX20 promoter site and repress TBX20 expression [109]. Interestingly, mutations in TFAP2B causes Char syndrome (OMIM #169100) characterized by facial dysmorphism, anomalies of the fifth finger and patent ductus arteriosus (PDA) [110]. Isolated PDA has also been linked to mutations in TFAP2B [111, 112] and a recent Tfap2B knock out study in mice reported phenotypes resembling the characteristics of Char syndrome [113]. TFAP2 isoforms form a complex with CITED2, CREBBP and EP300 [114, 115]. Mutations in the transcriptional co-activators CREBBP and EP300 are associated with Rubinstein–Taybi syndrome (OMIM #180849) displaying mental retardation, broad thumbs and toes, facial abnormalities, and in some cases, CHD [116, 117].

Genes encoding components of the cardiac sarcomere

Mutations in genes encoding cardiac structural proteins have also been connected to CHD. Several studies link mutations in the cardiac sarcomeric protein MYH6 (myosin heavy chain 6) to ASD [118–120]. Morpholino knock down of myh6 in the developing chicken heart implies that its functionality is required in the formation of the atrial septum [120]. Molecular regulation of MYH6 expression involves transcription factors such as GATA4 [121], TBX5 and MEF2C [122].

Other members of the contractile units in cardiovascular muscle include MYH7 and ACTC1. A mutation in MYH7 encoding myosin heavy chain 7 was shown to cause CHDs such as Ebstein’s anomaly and sepat defects [123]. Mutations in ACTC1 encoding the human α-cardiac muscle actin can cause ASD and morpholino knock down of Actc1 causes looping and atrial septal anomalies in chicken embryos [124].

Mutations in MYH11, encoding the major contractile protein of smooth muscle cells can cause thoracic aortic aneurysm and/or aortic dissection and PDA [125]. Mice homozygous for deletion of Myh11 show a delayed closure of the ductus arteriosus [126], which is connected to the shunting functions of smooth muscle cells upon birth [127, 128].

Genes encoding chromatin modifiers

Analysis of model organisms has shown that dynamic modification of chromatin structure serves as an important regulator of gene expression during heart development (reviewed in [129]). Genes that encode proteins which modify or bind to histones have been implicated as disease genes in syndromes causing heart defects. This evidence supports a functional link between chromatin modification and human heart development and defects.

Kabuki syndrome (OMIM #147920) is characterized by intellectual disability, craniofacial anomalies, skeletal and hand malformations. Abnormal organ development is also recurrent and includes CHD in approximately 50% of the cases [130]. Heart defects usually present in the form of septal defects and CoA [131]. Recently, Ng et al. [132] used exome sequencing to identify mutation of KMT2D (MLL2) as a major cause of Kabuki syndrome. KMT2D encodes a histone methyltransferase involved in di- and tri-methylation of the Lys-4 position of histone H3, which marks actively transcribed genes [133].

CHARGE syndrome (OMIM #214800) is characterized by growth retardation and malformation of eyes, ears, genitaI, choanae and heart defects—often in the form of outflow tract malformations [134–136]. Approximately two-thirds of the cases are caused by mutation of CHD7, which encodes a member of the chromodomain helicase DNA binding (CHD) family [134, 135, 137]. In vitro studies have shown that CHD7 binds DNA regions which correlate closely to regions of H3K4 methylation and regions with characteristics of enhancer elements. This hints that the protein is involved in transcriptional activation [138]. Recently, it was shown that CHD7 controls core components of the transcriptional circuit of neural crest cells and that CHD7 is essential for neural crest cell migration [139]. This function may explain the high frequency of outflow tract defects in CHARGE syndrome, as neural crest cells are known to play a crucial role in septation of the cardiac outflow tract [140].

In a recent study, Zaidi et al. [141] conducted a comprehensive screening of all protein coding genes in hundreds of patients with severe forms of CHD. In this study, whole-exomes of 362 children with CHD and their healthy parents were screened for de novo nucleotide variants by next-generation sequencing (NGS). De novo variants from these parent-offspring trios were compared to de novo variants identified in 264 healthy parent-offspring trios. The authors performed transcriptome profiling experiments to identify genes with a high expression in mouse embryonic hearts (HHE genes). In the trio datasets, they compared the number of de novo variants in genes, homologous to HHE
genes. This comparison yielded a significant higher rate of de novo mutations in CHD patients compared to controls. When they compared the frequencies of damaging mutations (i.e. splice-site mutations, nonsense mutations and mutations introducing frameshift) between the two groups, the differences were even more pronounced, with an odds ratio of 7.5 ($p = 0.001$). Interestingly, GeneOntology analysis of 249 de novo mutations identified in CHD patients revealed significant enrichment for mutations in genes involved in H3K4 methylation. Moreover, in CHD patients 27 % of the dam-

aging mutations within HHE genes were affecting proteins involved in H2K4 or H3K27 histone modification. These data suggest that genes involved in histone-modification are significant in the pathogenesis of isolated CHD.

Human genome analysis in combination with functional analysis of candidate genes in animal models has been instrumental in identifying the genes responsible for heart defects in several microdeletion syndromes (see below). Interestingly, several of these genes also encode chromatin modifying proteins, which support the potentially significant role of epigenetic mechanisms in both isolated and syndromic CHD.

Part II: chromosomal aberrations in congenital heart disease

Microscopically visible chromosomal aberrations are present in 8–18 % of CHD patients [142–144]. Furthermore, CHD is a characteristic part of the clinical spectrum in a significant number of syndromes caused by a chromosome abnormality. The most common chromosome syndrome associated with CHD is Down syndrome [145]. Congenital heart defects are seen in 45 % of individuals with Down syndrome, with the majority of cardiac defects being AVSD, ASD and VSD [146]. Cardiac defects are also found at a high frequency in other aneuploidy syndromes, including Turner syndrome (monosomy X), Edward syndrome (trisomy 18) and Patau syndrome (trisomy 13) [147–150].

CHD is a component of the clinical spectrum in a number of syndromes caused by submicroscopic chromosomal dele-
tions or duplications (listed in Table 2). Some of these syn-
dromes are well-studied microdeletion syndromes, for which the molecular defect has been known for many years. In addition, several novel microdeletion and microduplication syn-
dromes associated with CHD have recently been discovered due to the widespread use of molecular cytogenetic methods.

CHD candidate genes identified from microdeletion and microduplication syndromes

Genotype–phenotype comparisons in patients with microdeletion and microduplication syndromes have identified candidate CHD disease genes. Subsequent mutation screening of candidate genes in patients and studies of the genes and their product in animal models have substantially added to the understanding of CHD and cardiac development.

The majority of DiGeorge syndrome (DGS, OMIM #188400, also known as 22q11.2 deletion syndrome and velocardiofacial syndrome) are caused by a 3 Mb deletion in 22q11.2 [151]. 22q11.2 duplication syndrome (OMIM #608363) is caused by duplication of genomic material in 22q11.2. Most of the 22q11.2 duplications that have been reported are reciprocal to the common 3 Mb deletion involved in DGS [152].

The common 3 Mb deletion affects more than 50 genes, including the gene encoding the T-box transcription factor TBX1. It is generally accepted that haploinsufficiency of TBX1 significantly contributes to the CHD phenotype in DGS patients. Tbx1$^{-/-}$ mice display similar cardiac phenotypes to individuals with 22q11.2 DS [153, 154]. Conditional knock-out experiments in mice have shown that Tbx1 is required for proliferation of cardiac progenitors in the SHF—a cell population which contributes to the development of the cardiac outflow tract [155]. Additionally, point mutations in TBX1 have been reported in patients without the 22q11.2 deletion, but exhibit a clinical presentation similar to DGS [156, 157].

Transgenic mice overexpressing Tbx1 display phenotype similarities consistent with 22q11 duplication patients, including cardiac outflow tract defects. This suggests that correct gene-dosage of TBX1 is important for normal cardiac development [152, 158, 159].

Conversely, cases with cardiac defects carrying smaller (1.5 Mb) deletions within the common 3 Mb region, distal to TBX1 have also been reported [160–162], which implies that other genes in the 3 Mb region may contribute to the cardiac phenotype of DGS patients. An interesting candidate gene within this region is CRKL, encoding a protein kinase. Mice with targeted deletion of Crkl exhibit defective OFT development and VSDs [160, 163]. Furthermore, experiments with compound heterozygous Tbx1$^{-/-}$, Crkl$^{-/-}$ mice indicate a possible genetic interaction between the two genes, leading to the increased severity of the cardiac phenotypes in the double mutants [164]. A genetic interaction between Crkl and Fgf8 has also been shown [165], supporting a link among FGF8, TBX1 and CRKL in the pathogenesis of DGS (see below).

A high degree of phenotypic variability is a character-

istic feature of DGS and 22q11.2 duplication syndrome. Parts of this variation may perhaps be explained by variations in genes located within 22q11.2, with TBX1 as the most likely candidate. An alternative explanation involves epistasis, as TBX1 has been shown to regulate or interact with several proteins and signaling networks. Gene
Table 2 Microdeletion and microduplication syndromes with genomic copy number variation and CHD

| Syndrome | Chromosome region | Frequency of CHD among patients (%) | CHD candidate gene(s) in region<sup>a</sup> | Function of candidate gene(s)<sup>b</sup> | Reference (OMIM #) |
|----------|------------------|-------------------------------------|---------------------------------------------|------------------------------------------|------------------|
| **Microdeletion syndromes** | | | | | |
| 8p23.1 deletion syndrome | 8p23.1 | 94 | **GATA4** | GATA-binding TF | [195] |
| 17q23 microdeletion syndrome | 17q23 | 86 | **TBX2** | T-box TF | [216] (613355) |
| DiGeorge syndrome | 22q11.2 | 65–75 | **TBX1; CRKL** | T-box TF; Tyrosine kinase | [263] (188400) |
| 1p36 deletion syndrome | 1p36 | 71 | **DVL1** | WNT signaling component | [264] (607872) |
| 2q31.1 microdeletion syndrome | 2q31.1 | 70 | **SP3** | Sp TF | [265] |
| Kleefstra syndrome | 9q34 | 40 | **EHMT1** | H3K9 methyl transferase | [205, 206, 208] (610253) |
| 16p12.2-p11.2 microdeletion syndrome | 16p12.2-p11.2 | 60 | N/A | | [266] (613604) |
| Jacobsen syndrome | 11q23-qter | 56 | N/A | | [267] (147791) |
| Wolf–Hirschhorn syndrome | 4p16.3 | 50 | **WHSC1; FGFRL1** | H3K36 methyl transferase; fibroblast growth factor receptor | [268] (194190) |
| Williams–Beuren Syndrome | 7q11.23 | 53–85 | **ELN; BAZ1B** | Elastin; subunit of chromatin remodeling complex | [180] (194050) |
| Smith–Magenis syndrome | 17p11.2 | 40–45 | **MAPK7**<sup>b</sup> | MAP kinase | [269, 270] (182290) |
| Koolen-De Vries syndrome | 17q21.31 | 27–36 | **KANSL1**<sup>c</sup> | Subunit of NSL histone acetylation complex | [210, 212] (610443) |
| 1q21.1 deletion syndrome | 1q21 | 29 | **GJA5** | Connexin 40 | [197, 271] |
| Miller–Dieker lissencephaly syndrome | 17p13.3 | 22 | N/A<sup>d</sup> | | [272, 273] (247200) |
| Sotos syndrome | 5q35 | 21 | **NSD1** | H3K36 methyl transferase | [274–276] (117550) |
| Brachydactyly-mental retardation syndrome | 2q37 | 20 | **HDAC4** | Histone deacetylase | [277, 278] (600430) |
| 15q13 microdeletion syndrome | 15q13 | 15 | N/A | | [279, 280] (612001) |
| **Microduplication syndromes** | | | | | |
| 16p13.3 microduplication | 16p13.3 | 40 | **CREBBP** | Histone acetyltransferase | [281] (613458) |
| 16p13.11 microduplication | 16p13.11 | 20 | **MYH11**<sup>e</sup> | Smooth muscle myosin HC | [282] |
| Potocki–Lupski syndrome | 17p11.2 | 50 | **MAPK7** | MAP kinase | [283, 284] (601883) |
| 22q11.2 duplication syndrome | 22q11.2 | 15 | **TBX1** | T-box TF | [285] (608363) |
| **Chromosomal aneuploidy** | | | | | |
| Patau syndrome | 47, +13 (trisomy 13) | 86 | N/A | | [150] |
| Edward syndrome | 47, +18 (trisomy 18) | 61–94 | N/A | | [147, 148] |
| Down syndrome | 47, +21 (trisomy 21) | 50 | N/A | | [146] (190685) |

<sup>a</sup> Genes causing heart defects when deleted in mice (http://www.informatics.jax.org) (bold) and/or by point mutations in additional patients with CHD as part of the clinical spectrum (underlined)

<sup>b</sup> Point mutations in RAI1 causes Smith–Magenis syndrome, but CHD have not been reported in patients with point mutations in RAI1 and cardiac defects are not observed in the Rail mouse model [286]

<sup>c</sup> One out of four KDVS patients with point mutations in KANSL1 had CHD

<sup>d</sup> The lissencephaly phenotype of MDLS is caused by haploinsufficiency of the PAFAH1B1 gene (also known as LIS1) [287, 288], but it is presently unknown which gene is responsible for heart defects in MDLS patients

<sup>e</sup> TF transcription factor
expression profiling of tissues in the pharyngeal region from mouse models with targeted deletion of Tbx1, have identified several Tbx1 target genes, which include genes involved in homeostasis of retinoic acid (RA) [166–168]. Interestingly, RA regulates Tbx1 expression [169], thus there seems to be a dual relationship between Tbx1 expression and RA signaling. During development of the pharyngeal arches Tbx1 expression in the pharyngeal endoderm is regulated by the Hedgehog signaling pathway though the action of forkhead transcription factors [170, 171]. Tbx1 itself regulates the expression of FGF8 in the SHF and in the pharyngeal endoderm [172, 173]. A genetic interaction among Tbx1, Six1/Eya1 and Fgf8 was recently demonstrated in mouse models [174]. Further, Tbx1 can act as a negative modulator of BMP signaling by binding BMP receptors [175].

Williams–Beuren syndrome (WBS, OMIM #194050) is caused by deletion of genomic material in 7q11.23. Most patients with WBS are heterozygous for a 1.5–1.8 Mb deletion encompassing ~28 genes [176–179]. Cardiovascular abnormalities are present in 75% of individuals with WBS, predominantly in the form of supravalvular aortic stenosis (SVAS) and pulmonary arterial stenosis [180]. In 6–10% of cases, aortic or mitral valve defects are also seen, and other so-called “atypical” cardiac defects such as ASD, VSD, and TOF are observed in a significant fraction of the patients [180, 181].

The ELN gene, encoding elastin, is believed to be the gene responsible for SVAS in WBS. Patients with atypical deletions including only ELN and LIMK1 genes and SVAS have been reported [182, 183]. In addition, point mutations in ELN are associated with familial and sporadic SVAS [184, 185]. Targeted deletion of the Eln gene in mice results in reduced aortic lumen diameter due to subendothelial accumulation of smooth muscle cells [186].

However, deletion of ELN does not explain the occurrence of the atypical heart defects in a proportion of WBS patients. Results gained from a recently reported mouse model with targeted deletion of Baz1b, indicate that deletion of this gene may account for these defects. Baz1b is located within the WBS common deleted region, and homozygous Baz1b−/− mice exhibit a range of cardiovascular defects, which include ASD, VSD, trabeculation defects, coarctation of the aorta (COA), hypoplastic pharyngeal arch artery and a low frequency of DORV [187]. Baz1b (also known as WSTF) acts as a subunit in three ATP-dependent chromatin remodeling complexes; the WSTF including nucleosome assembly complex (WINAC) [188], the WICH complex (WSTF-ISWI chromatin remodeling complex) [189] and the B-WICH complex [190]. These complexes are important for gene regulation, DNA replication and DNA repair [189, 191]. Thus, the cardiac phenotypes of Baz1b knockout mice and the chromatin remodeling function of Baz1b suggest that some of the phenotypes involved in WBS, including “atypical” heart defects, may be caused by epigenetic effects.

Wolf–Hirschhorn syndrome (WHS, OMIM #194190) is caused by microdeletions in 4p16.3. Genotype–phenotype comparisons in patients with submicroscopic deletions suggest that haploinsufficiency of the gene encoding the histone lysine methyltransferase WHSC1 (also known as NSD2) contributes significantly to the WHS phenotype [152, 192]. A recently published investigation of mice with targeted deletion of the H3K36me3-specific histone methyltransferase gene Whsc1 puts forth Whsc1 as another component in heart development [193]. The Whsc1−/− mutant mice displayed ASD and VSD, and co-immunoprecipitation experiments with nuclear extracts prepared from embryonic hearts showed that Whsc1 interacts with the cardiac transcription factor Nkx2-5. Furthermore, ChIP assays demonstrated that Whsc1 cooperates with Nkx2-5 in the transcriptional regulation of target genes. Cross-breeding experiments with Whsc1+/− and Nkx2-5−/− mice suggested a genetic interaction between the two genes during cardiac septal formation. Another candidate gene for heart defects in WHS is the FGFR1 gene, which encode a member of the fibroblast growth factor receptor family. During mouse development Fgfr1 is expressed in the brain, cranial placodes, pharyngeal arches, somites and heart [194]. Targeted deletion of Fgfr1 in mice can result in a range of developmental defects, including heart defects in the form of VSD, and both semilunar and atrioventricular valve deformation [194].

Cardiac defects are observed in 94% of cases with interstitial deletions in 8p23.1 [195]. The defects range from isolated septal defects to complex heart defects like TOF and hypoplastic left heart syndrome (HLHS). A proportion of the patients carry a ~3.7 Mb recurrent deletion flanked by low copy repeats, although some patients have larger deletions that may extend to the 8p telomere. The gene encoding the cardiac zinc finger transcription factor GATA4 is located within the recurrent deletion, and it is well documented that this gene is associated with congenital heart defects. Mutations in GATA4 cause human CHD, often in the form of septal defects, but other defects have been reported [89, 91, 196]. Mice homozygous for targeted deletion of Gata4 display early defects in cardiogenesis [93, 94], and phenotypic characterization of mice homozygous for a hypomorphic allele of Gata4 suggests that haploinsufficiency of Gata4 can cause CHD [95]. Gata4 interacts with several other transcription factors during cardiac development, including Nkx2-5, Tbx5,
The widespread use of molecular cytogenetic methods like fluorescent in situ hybridization (FISH) and especially array comparative genome hybridization (array CGH) in clinical genetics laboratories has led to the recent delineation of a number of microdeletion and microduplication syndromes, which incorporate CHD as a component of their clinical spectrum (Table 2).

The minimal deleted region in 1q21.1 deletion syndrome contains the GJA5 gene [197]. A recent screen of 807 TOF cases revealed significant enrichment of small duplications encompassing GJA5, thus providing convincing evidence for a link between GJA5 and CHD [152, 192, 198]. Cardiac defects have been reported in a proportion of mice with targeted deletion of Gja5 [199, 200], suggesting that haploinsufficiency of GJA5 may be responsible for cardiac defects in some individuals with 1q21.1 deletions. GJA5 encodes the cardiac gap junction subunit Connexin 40, which is expressed in the atrial myocardium and the atrioventricular conduction system [201, 202]. Gap junctions are cell membrane channels that interconnect the cytoplasm of neighboring cells. In the heart, these channels contribute to the atrioventricular conduction [203, 204], but at present there is no proposed mechanism describing how GJA5 haploinsufficiency results in structural heart defects.

Molecular delineation of 9q34 microdeletions and mapping of the chromosomal breakpoints in a patient with a t(X;9) translocation suggested that the EHMT1 gene is responsible for Kleefstra syndrome (KS, OMIM #610253) [205–207]. Mutation screening in patients without deletions in 9q34 subsequently confirmed that haploinsufficiency of EHMT1 causes KS [205, 208]. Approximately 40 % of patients with KS and deletion of 9q34 have CHD, and the presence of CHD in five out of eleven KS patients with point mutations in EHMT1 confirm that this gene is responsible for CHD in KS. EHMT1 encodes euchromatic histone-lysine N-methyltransferase 1, which regulates transcription by methylation of histone H3 lysine 9 (H3K9Me2) in euchromatic DNA [209].

Koolen-De Vries syndrome (KDVS, OMIM #610443) is caused by recurrent deletions in 17q21.31. Between 27 and 36 % of KDVS patients have CHD [210, 211]. Recent delineation of the critical region of 17q21.31 and mutation screening of KDVS patients without deletion of 17q21 revealed that KDVS is caused by haploinsufficiency of KANSL1 [212, 213]. One out of four patients with point mutations in KDVS has CHD, hinting that KANSL1 is a CHD disease gene, although further patient data is needed to confirm this link. KANSL1 encodes a member of the male specific lethal (MSL) complex initially described in Drosophila (reviewed in [214]). Within the MSL complex KANSL1 interacts with KAT8, a histone acetyltransferase which regulates gene expression through acetylation of H4 lysine 16 (H4K16) [215].

Another interesting CHD candidate gene is TBX2, which is located within the deleted region in 17q23 deletion syndrome [216]. TBX2 is expressed in non-chamber myocardium of the developing heart, and mice with targeted mutation in Tbx2 have defects in the development of the atrioventricular canal (AVC) and the OFT [217]. It has been hypothesized that TBX2 is involved in cardiac chamber development and functions as a local repressor of the chamber-specific gene program in non-chamber regions like the AVC and OFT [218, 219].

Pathogenic copy number variants identified in cohorts of CHD patients

Array CGH and similar methods have been used to screen cohorts of CHD patients for pathogenic CNVs in the form of duplications and deletions. Since 2007, 14 whole-genome CNV screening studies have been reported, comprising more than 5,000 patients (Table 3, [220–234]). The reported studies show large differences, which include size and phenotypic composition of patient cohorts and the experimental and analytical setup, thus it is somewhat difficult to compare the results. Nevertheless, we find it safe to conclude that pathogenic CNVs are found among a significant portion of CHD patients.

The highest frequency of pathogenic CNVs is found among patients with CHD and extra-cardiac anomalies. Based on the current reports [220, 224, 228, 230, 233, 234] we estimate that pathogenic CNVs are present in 15–20 % of patients with CHD and extra-cardiac anomalies.

Among patients with isolated CHD, the frequency of pathogenic CNVs is significantly lower. Here, we estimate the frequency to be between 4 and 14 % [221, 222, 225, 231, 232]. However, this estimate should be treated with caution, due to the aforementioned large differences in study design.

Identification of disease genes and pathways from CNVs detected in cohorts of CHD patients

In principle, CNVs identified as pathogenic in CHD patients should contain one or more dosage sensitive cardiac developmental genes. Thus, each pathogenic CNV, or at least overlapping CNVs should define a disease locus for
### Table 3 CNV screens in patients with heart defects

| Patients | Phenotype of patients\(a\) | Microarray type | Main results | Candidate genes in CNVs\(b\) | Reference |
|----------|-----------------------------|----------------|-------------|-------------------------------|-----------|
| 60       | Congenital heart disease and extracardiac abnormalities | In-house-made microarray containing BAC/PAC\(^c\) clones. Average genomic distance of probes were 1 Mbp | CNVs considered to be causal were identified in 10 (17 %) patients | \(EHMT1, NKX2-5, NOTCH1, NSD1\) | [233] |
| 105      | Congenital heart disease with and without extracardiac abnormalities. Subjects with documented syndromes were excluded | In-house-made microarray containing 32 k overlapping BAC clones | Rare de novo or inherited CNVs (0.34–13.9 Mb in size) were detected in 18 (17 %) patients | \(GJA5, LTBP1, TBX1\) | [222] |
| 40       | Congenital heart disease with and without extracardiac abnormalities | NimbleGen Systems, Inc. whole-genome 385 K oligo array | Seven large CNVs were identified in 5 (12.5 %) patients | N/A | [230] |
| 114      | Tetralogy of Fallot (TOF) | Affymetrix Genome-Wide Human SNP Array 6.0 | Eleven (9.6 %) rare de novo CNVs (>20 kb) were identified in 114 TOF trios | \(JAG1, NOTCH1, RAB10, RAF1, TBX1\) | [225] |
| 150\(a\) | Congenital heart disease and extracardiac abnormalities | In-house-made microarray containing BAC/PAC clones. Average genomic distance of probes were 1 Mbp | CNVs considered to be causal were identified in 26 (17.3 %) patients | \(ATRX, CREBBP, EHMT1, FOXC1, GATA4, NOTCH1, RAI, TBX1\) | [220] |
| 46       | Isolated congenital heart disease | Affymetrix Genome-Wide Human SNP Array 6.0 | De novo CNVs were identified in two (4 %) patients | \(GJA5, NOTCH1, PDGFR\(A\), TBX1\) | [221] |
| 58       | Congenital heart disease and extracardiac abnormalities | Affymetrix GeneChip 100 K microarray | Potentially pathogenic CNVs (0.2–9.6 Mb in size) were detected in 12 (20.7 %) patients | \(ADAM19, HAND1, MESP1, NRP1, NTRK\) | [224] |
| 53       | Hypoplastic left heart syndrome (HLHS) | Agilent customized genome-wide 400 K array | Thirty-three rare non-polymorphic CNVs (2–1,554 kb in size) were detected in 25 (47 %) patients | \(BMPR2, ZNF423\) | [227] |
| 262      | Heterotaxy (patients with D-transposition of the great arteries were also included in the sample) | Illumina 610Quad Beadchip platform | Forty-five previously unrecorded genic CNVs (0.27–25 Mb in size) were identified in 39 (14.5 %) patients. A significant (\(p = 1.5e-4\)) burden of rare genic CNVs were found in HTX cases (14.5 %) compared to controls (7.4 %) | \(GALNT11, NEK2, NUP188, ROCK2, TGFBR2\) | [223] |
| 43       | HLHS | NimbleGen Systems, Inc. whole-genome 385 K oligo array | A significant (\(p < 0.03\)) burden of CNVs were found in patients (4.6/subject) compared to controls (2.94/subject). The burden of unique CNVs in CHD patients was not found to be significant | N/A | [229] |
| Patients | Phenotype of patients\(^d\) | Microarray type | Main results | Candidate genes in CNVs\(^g\) | Reference |
|---|---|---|---|---|---|
| 67\(^b\) | Left-sided congenital heart disease (BAV, AS, COA, HLHS) | Affymetrix Human Genome-Wide SNP Array 6.0 | A total of 73 unique inherited or de novo CNVs (>20 kb) were identified in 54 individuals | ADORA2B, ANG, ACACALC, COPS3, CRMP1, CTND1, ERCC5, EVC2, FLI1, GRP6L, HS171B10, ITGA10, LIMS1, MAPK7, MPA4, MSX1, MTHFD2, NGER, PLA2G2A, PRPSAP2, RASD1, SEBF1, SMC1A, UKL2 | [226] |
| 2,539 | Isolated congenital heart disease (808 TOF and 1,448 other CHDs). Subjects with documented syndromes known to cause CHD were excluded | Illumina 660 W-Quad SNP platform | A significant \((p = 0.008)\) burden of rare genic CNVs were found in CHD cases (7.8 %) compared to controls (4.4 %) | CNOT6, EDL3, GATA4, GJAS, HAND2, PM2K and 13 genes in the Wnt-signaling pathway (CDH1, CDH2, CTBP1, CTNB1, FAT1, LRPS1, NFAT1, PCDH13, PCDH17, PCDH8, PRKCB, PRKCS, WNT7B) | [232] |
| 203 + 511\(^c\) | Congenital heart disease and extracardiac abnormalities. | Customized 105 k oligonucleotide arrays manufactured by Agilent. Average resolution of 30 kb, with denser coverage at disease loci | A total of 55 rare CNVs (>50 kb) were identified in patients from the discovery cohort. Sixteen of these CNVs were identified in the second cohort | PDE4A, NALCN, ANKRD11, SOX7, GATA4, CRK, CAMTA2, CECR1 | [228] |
| 433 | Tetralogy of Fallot-pulmonary stenosis or pulmonary atresia and ventricular septal defect. Subjects with documented syndromes were excluded | Affymetrix Genome-Wide Human SNP Array 6.0 | 47 large (>500 kb) rare CNVs were found in 43 (9.9 %) patients | ANGPT2, ARHGEF10, ARHGEF4, BARD1, BBS9, C12orf66, CASP1, CASP12, CASP4, CASP5, CCDC148, CDH19, CHL1, CHRM3, CHST8, CNPD2, CNN2, CRKL, DIP1, DSHA11, EDL3, FGG10, FOXO3B, FSTL3, FSTL4, GJA5, GMDS, GNA11, HIRA, HNF1B, HRIP3, IDS, KCNB2, KIAA1609, LBH, MAPK3, NBEA, NFAT1C, NXX, PAR6DG, PDS5B, PLXNA2, PP1K, PPP4C, PTB1, RA1, RIP4, SEMA3D, SEMA5A, SFPRQ, SLCA5A4, SNX8, SOX4, SPG20, TBX1, TBX6, TNNFSF11, VCAN, WDR18, WNK3, ZNF347 | [231] |
| 945 | Congenital heart disease with and without extracardiac abnormalities | Affymetrix Genome-Wide Human SNP Array 6.0 | Known CHD-related chromosomal abnormalities\(^f\) were identified in 135 (14.3 %) patients. Large, rare CNVs (0.22–32.1 Mb in size) were identified in 35 (3.7 %) patients | FKBP6, FLN, GTF2IRD1, GATA4, CRKL, TBX1, ATRX, GPC3, BCR, ZIC3, FLNA, MID1, PRKAB2, FMOD, CHD1L, BCL9, ACP6, GJAS, HRAS, GATA6, RUNX1 | [234] |

Genes known to cause CHD in humans are underlined, genes with reported cardiovascular system involvement (e.g., from targeted deletion in mice) are bold

\(^a\) Includes 60 patients from Thienpont et al. [233]

\(^b\) A total of 174 patients from 67 families

\(^c\) A discovery cohort of 203 patients and a second independent cohort of 511 patients were analyzed

\(^d\) AS aortic stenosis, BAV bicuspid aortic valve, COA coarctation of the aorta, HLHS hypoplastic left heart syndrome, TOF tetralogy of Fallot

\(^e\) BAC bacterial artificial chromosome, PACP1-derived artificial chromosome

\(^f\) Trisomy 21 \((n = 80)\), trisomy 18 \((n = 1)\), 22qDS \((n = 42)\), Turner syndrome \((n = 8)\), William’s syndrome \((n = 3)\), and Triple X syndrome \((n = 1)\)

\(^g\) Candidate genes suggested by the authors
CHD and it therefore should be possible to use CNVs to detect CHD disease genes. Several groups have reported identification of CNVs spanning genes, which span genes previously recognized to cause CHD in animal models (Table 3), thereby providing a plausible link between these genes and CHD in humans.

However, many of the identified CNVs do not contain a well-established cardiac developmental gene. These CNVs often contain several genes, although only one is likely to be the gene responsible for CHD. Three approaches have been utilized to identify the causal genes in such cases: (1) narrowing of the locus by comparison of multiple samples with overlapping CNVs, (2) in silico gene prioritization and (3) functional investigations of candidate genes within the CNVs.

Hitz et al. [226] used Endeavour [235] to test for enrichment of angiogenesis-associated genes within 73 CNVs identified in patients with left-sided CHD. They also searched for genes with expression in the developing heart in serial analysis of gene expression (SAGE) and public databases. By combining these prioritization methods, they identified 25 CHD candidate genes (Table 3). Soemedi et al. [232] performed genomic region annotation enrichment analysis on rare deletions and duplications identified in 2,256 CHD cases. They found enrichment of 13 genes encoding proteins involved in the WNT signaling pathway (Table 3). Silversides et al. [231] performed a systematic review of genes within rare CNVs identified among 433 cases with TOF and identified 62 CHD candidate genes (Table 3). They also assessed whether genes, in predefined gene-sets derived from GeneOntology (GO) annotations and pathway and protein domain databases, were significantly overrepresented in CNVs detected in TOF cases compared to controls. They found enrichment of gene-sets belonging to five functional clusters: vasculature development, chromosome organization, cell motility, chemotaxis and neuron projection and development. Lalani et al. [228] identified eight candidate genes in CNVs identified in patients with CHD and extracardiac anomalies (Table 3). They grouped genes within enriched CNVs based on GO categories and found enrichment for genes encoding proteins involved in G-protein coupled receptor internalization, hemopoiesis and cytoskeleton organization. Furthermore, they analyzed protein–protein interactions between proteins encoded by candidate genes in CNVs identified in patients and a set of 276 proteins from GO cardiac development categories. They identified 11 proteins with at least one connection with a human cardiac-specific protein (significant at \( p = 0.03 \)).

Thienpont et al. [236] identified TAB2 as a dosage sensitive CHD disease gene by comparing overlapping CNVs within 6q25. The overlapping region of seven CNVs identified in CHD patients revealed a CHD locus containing 11 candidate genes, including TAB2. For prioritization of the candidate genes in the locus and surrounding genomic region, the authors performed in silico analyses of 105 genes in 6q24–25, using an adapted version of Endeavour [235]. This analysis predicted TAB2 as the highest-ranking candidate gene in 6q24–25. Further functional analyses of TAB2 in human embryonic heart tissues and zebrafish suggested that TAB2 is a cardiac developmental gene. Point mutations localized within TAB2 in two unrelated CHD patients and mapping of a translocation breakpoints within TAB2 in a CHD family segregating a t(2;6) translocation, further verified TAB2 as a CHD disease gene.

Fakhro et al. [223] performed whole-genome CNV screening of 262 patients with Heterotaxy and isolated TGA. They identified 45 unrecorded gene-containing CNVs, including two different CNVs affecting TGFBR2. Evaluation of candidate genes using in situ hybridization and Morpholino-based gene knock-down in X. tropicalis showed that the genes tgb2r, rock2, galnt11, nek2 and nup188 are involved in left–right patterning of the heart (Table 3). ROCK2 and NEK2 are ciliary proteins, thus this study confirmed the importance of cilia and TGF-β signaling in LR patterning [237]. In addition, this study identified two novel genes (GALNT11 and NUP188) with unknown functions in LR development.

The molecular pathology of congenital heart disease

Cardiac development is controlled by a large number of signaling pathways, which are tightly regulated in time and space, and interact in complex developmental networks [34]. The CHD disease genes, which have been identified to date, suggest that all aspects of developmental signaling pathways may be involved in human CHD: from ligands (e.g. JAG1) and receptors (e.g. NOTCH, PDGFRA), across down-stream signaling effectors (e.g. PTPN11, SMAD6), to transcription factors (e.g. GATA4, NKX2-5) and targets (e.g. ACTC1, MYH6) (Fig. 1). Moreover, discoveries of disease genes encoding histone-modifying proteins (e.g. CHD7, KMT2D), suggest that epigenetic regulation of an unknown number of target genes, may add an additional layer of regulation on consensus cardiac developmental networks.

Lage et al. [238] have recently shown that a wide range of CHD risk factors, functionally converge in complex, yet discrete, protein networks driving heart development. These findings, combined with the potentially hundreds of CHD disease genes [141], suggest that CHD may be caused by a very large number of combinations of mutations and environmental risk factors.

Reduced penetrance of CHD are often observed in human pedigrees (e.g. [239], unpublished observations in Danish pedigrees) and in carriers of CNVs known to
cause CHD (see Table 2 and discussions in text). Some of the reduced penetrance may simply be due to unidentified asymptomatic heart defects in some carriers, but may also be caused by epistasis. Several examples of epistasis in mouse models are mentioned in the text above. Winston et al. [240] performed a systematic study of the influence of genetic background on the expression of heart defects in \( Nkx2.5^{+/−} \) heterozygous mice. The authors compared \( Nkx2.5^{+/−} \) heterozygous C57Bl/6 mice with \( Nkx2.5^{+/−} \) heterozygous F1 progeny from crosses with two other mouse strains. The data showed that the F1 hybrid mice presented with a significantly lower incidence of septal defects compared to mice with the original C57Bl/6 background. The authors suggest that modifying alleles can either direct the manifestation of a cardiac developmental defect or buffer the effect from perturbations. The latter situation, which was the case in the study, may ensure robustness of normal heart development.

How the large heterogeneity in CHD and potentially large epistatic effects translates into lesions in the personal genome of the individual patient remains to be investigated. One possible scenario could be that individual combinations of several risk alleles may be the cause of CHD in part of the patients.

Future perspectives

It was recently demonstrated that exome-sequencing is a powerful tool for identification of de novo mutations in CHD [141]. It is very likely that more studies based on exome-sequencing will reveal new CHD disease genes in the near future. The high number of variants identified in exome-sequencing experiments is a big challenge in very heterogeneous disorders like CHD. Thus, it is likely that such studies will be performed on large numbers of parent-offspring trios or on families with dominant or recessive inherited CHD.

The past 5 years have shown that analysis of genome rearrangements in the form of CNVs, translocations or inversions can lead to detection of new CHD disease genes or loci. The technology for mapping such rearrangements is continuously improving, and breakpoints in balanced translocations and inversions can now be mapped within days using NGS [241].

Untreated, CHD is a disorder with a high mortality rate, therefore a large part of the disease causing mutations are likely rare in populations due to negative selection. However, it is also possible that some variants associated with CHD may escape negative selection. Such variants may be discovered through genome wide association studies, as has recently been demonstrated [242–244].

Interesting therapeutic opportunities could arise from the current knowledge of the molecular pathogenesis of CHD. A significant part of CHD seems to be caused by mutations which perturb complex developmental networks. These networks are characterized by extensive communication within and between specific signaling pathways, and with the environment. Thus, given the apparent epistatic effects observed in patients and animal models, it should be possible to manipulate the signaling pathways in the developmental networks with synthetic agonists or antagonists, and thereby alleviate effects from mutations or redirect...
signaling events towards normal heart development. A recent study suggests that this could be possible someday. Tian et al. [245] showed that defects in the cardiac inflow tract and AV canal (resembling complete CAVC in humans) in Wnt2−/− mice, could be rescued by transient pharmacological activation of Wnt signaling with LiCl.

Naturally, such therapeutic opportunities are presently very hypothetical, and to become reality, much more knowledge about the molecular genetics and the molecular pathology of CHD are needed. Combining human genetics/genomics with functional studies in cell models or animal models like zebrafish, Xenopus frogs, chicken or mice are likely to have the greatest impact on our understanding of the molecular pathology in human CHD.

Acknowledgments We thank Josie Bodle for language editing of the manuscript. LAL and TAA were supported by The Danish Council for Independent Research. KDT was supported by the Lundbeck foundation. Wilhelm Johannsen Centre for Functional Genome Research is established by the Danish National Research Foundation.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A (2008) Prevalence of congenital heart defects in metropolitan Atlanta, 1998–2005. J Pediatr 153(6):807–813
2. Hoffman JI (1995) Incidence of congenital heart disease: II. Prenatal incidence. Pediatr Cardiol 16(4):155–165
3. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD (2008) ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 118(23):e714–e833
4. Parrott A, Ware SM (2012) The role of the geneticist and genetic counselor in an ACHD clinic. Prog Pediatr Cardiol 34(1):15–20
5. Vandenbargen LN, Levin M (2013) A unified model for left-right asymmetry? Comparison and synthesis of molecular models of embryonic laterality. Dev Biol 379(1):1–15
6. Tanaka Y, Okada Y, Hirokawa N (2008) FGF-induced vesicular release of Sonic hedgehog and retinoic acid in leftward nodal flow is critical for left-right determination. Nature 455(7209):172–177
7. McGrath J, Somlo S, Makova S, Tian X, Brueckner M (2003) Two populations of node monocilia initiate left-right asymmetry in the mouse. Cell 114(1):61–73
8. Nonaka S, Shiratori H, Sajioh Y, Hamada H (2002) Determination of left-right patterning of the mouse embryo by artificial nodal flow. Nature 418(6893):96–99
9. Nonaka S, Tanaka Y, Okada Y, Takeda S, Harada A, Kanai Y, Kido M, Hirokawa N (1998) Randomization of left-right asymmetry due to loss of nodal cilia generating leftward flow of extracellular fluid in mice lacking KIF3B motor protein. Cell 95(6):829–837
10. Ramsdell AF (2005) Left-right asymmetry and congenital cardiac defects: getting to the heart of the matter in vertebrate left-right axis determination. Dev Biol 288(1):1–20
11. Yoshioka H, Meno C, Koshiha K, Sugihara M, Itoh H, Ishimaru Y, Inoue T, Ohuchi H, Semina EV, Murray JC, Hamada H, Noji S (1998) Pitx2, a bicoid-type homeobox gene, is involved in a left-right-signaling pathway in determination of left-right asymmetry. Cell 94(3):299–305
12. De Luca A, Sarkozy A, Consoli F, Ferese R, Guida V, Dentici ML, Mingarelli R, Bellacchio E, Tuo G, Limongelli G, Digilio MC, Marino B, Dallapiccola B (2010) Familial transposition of the great arteries caused by multiple mutations in laterality genes. Heart 96(9):673–677
13. Mohapatra B, Casey B, Li H, Ho-Dawson T, Smith L, Fernbach SM, Molinari L, Niesh SR, Jefferies JL, Craigen WJ, Tovbin JA, Belmont JW, Ware SM (2009) Identification and functional characterization of NODAL rare variants in heterotaxy and isolated cardiovascular malformations. Hum Mol Genet 18(5):861–871
14. Kosaki K, Bassi MT, Kosaki R, Lewin M, Schauer G, Casey B (1999) Characterization and mutation analysis of human LEFTY A and LEFTY B, homologues of murine genes implicated in left-right axis development. Am J Hum Genet 64(3):712–721
15. Kosaki R, Gebbia M, Kosaki K, Lewin M, Bowers P, Tovbin JA, Casey B (1999) Left-right axis malformations associated with mutations in ACVR2B, the gene for human activin receptor type IB. Am J Med Genet 82(1):70–76
16. Karkera JD, Lee JS, Roesler E, Banerjee-Basu S, Ouspenskaia MV, Mez J, Goldmuntz E, Bowers P, Tovbin J, Belmont JW, Basexavis AD, Schier AF, Muenke M (2007) Loss-of-function mutations in growth differentiation factor-1 (GDF1) are associated with congenital heart defects in humans. Am J Hum Genet 81(5):987–994
17. Goldmuntz E, Bamford R, Karkera JD, dela Cruz J, Roesler E, Muenke M (2002) CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle. Am J Hum Genet 70(3):776–780
18. Spierling S, Grimm CH, Dunkel I, Mebus S, Spierling HP, Ebner A, Galli R, Lehrach H, Fusch C, Berger F, Hammer S (2005) Identification and functional analysis of CITED2 mutations in patients with congenital heart defects. Hum Mutat 26(6):575–582
19. Ware SM, Peng J, Zhu L, Fernbach S, Colicos S, Casey B, Tovbin J, Belmont JW (2004) Identification and functional analysis of ZIC3 mutations in heterotaxy and related congenital heart defects. Am J Hum Genet 74(1):93–105
20. French VM, van de Laar IM, Wessels MW, Rohe C, Roos-Hesselink JW, Wang G, Frohn-Mulder IM, Severijn AJ, de Graaf BM, Schot R, Breedveld G, Mientjes M, Jodet E, Jiang Z, Verkerk A, Swagemakers S, Venselaar H, Rahimi Z, Najmabadi F, Parenteau J, Drabe JF, Bertoli-Avella AM (2012) NPHP4 variants are associated with pleiotropic heart malformations. Circ Res 110(12):1564–1574
21. Otto EA, Schermer B, Obara T, O’Toole JE, Hiller KS, Mueller AM, Ruf RG, Hoefele J, Beekmann F, Landau D, Foreman JW, Goodship JA, Strachan T, Kispert A, Wolf MT, Gagnadoux JA, Casey B, Robinson JA, Aveller AM (2003) Mutations in INVS encoding inverson cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat Genet 34(4):413–420
22. Chaki M, Hoefele J, Allen SJ, Ramaswami G, Janssen S, Bergmann C, Heckenlively JR, Otto EA, Hildebrandt F (2011) Genotype-phenotype correlation in 440 patients with NPHP-related ciliopathies. Kidney Int 80(11):1239–1245
23. Gebbia M, Ferrero GB, Pilia G, Bassi MT, Aylishworth A, Penman-Split M, Bird LM, Bamforth JS, Burn J, Schlessinger D, Nelson DL, Casey B (1997) X-linked situs abnormalities result from mutations in ZIC3. Nat Genet 17(3):305–308
24. Megarbane A, Salem N, Stephan E, Ashoush R, Lenoir D, Delague V, Kassab R, Loisset J, Bouvagnet P (2000) X-linked transposition of the great arteries and incomplete penetrance among males with a nonsense mutation in ZIC3. Eur J Hum Genet 8(9):704–708
25. Purandare SM, Ware SM, Kwan KM, Gebbia M, Bassi MT, Deng JM, Vogel B, Behringer RR, Belmont JW, Casey B (2002) A complex syndrome of left-right axis, central nervous system and axial skeleton defects in Zic3 mutant mice. Development 129(9):2293–2302
26. Ware SM, Harutyunyan KG, Belmont JW (2006) Heart defects in X-linked heterotaxy: evidence for a genetic interaction of Zic3 with the nodal signaling pathway. Dev Dyn 235(6):1631–1637
27. Sutherland MJ, Wang S, Quinn ME, Haaning R, Ware SM (2013) Zic3 is required in the migrating primitive streak for node morphogenesis and left-right patterning. Hum Mol Genet 22(10):1913–1923
28. Lenhart KF, Holtzman NG, Williams JR, Burdine RD (2013) Integration of nodal and BMP signals in the heart requires FoxH1 to create left-right differences in cell migration rates that direct cardiac asymmetry. PLoS Genet 9(1):e1003109
29. Roeslaller E, Ouspenskaia MV, Karkera JD, Velez JL, Konitpong A, Lachab F, Bowers P, Belmont JW, Tovbin JA, Goldmuntz E, Feldman B, Muenke M (2008) Reduced NODAL signaling strength via mutation of several pathway members including FOXH1 is linked to human heart defects and holoprosencephaly. Am J Hum Genet 83(1):18–29
30. von Both I, Silvestri C, erdemir T, Lickert H, walls JR, Henkelmann C, Heckenlively JR, Otto EA, Smoot LB, Pu WT, Donahoe PK, Tommerup N, Brunak S, Seidman CE, Seidman JG, Larsen LA (2010) Dissecting spatio-temporal protein networks driving human heart development and related disorders. Mol Syst Biol 6:381
31. Srivastava D (2001) Genetic assembly of the heart: implications for congenital heart disease. Annu Rev Physiol 63:451–469
32. de la Pompa JL, Epstein JA (2012) Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev Cell 22(2):244–254
33. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, Qi M, Trask BJ, Kuo WL, Cochran J, Costa T, Pierpont ME, Rand EB, Piccoli DA, Hood L, Spinner NB (1997) Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 16(3):243–251
34. Ota D, Elkahhoun AG, Pike BL, Okajima K, Krantz ID, Genin A, Piccoli DA, Meltzer PS, Spinner NB, Collins FS, Chandrasekharappa SC (1997) Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 16(3):235–242
35. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA (1999) Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 29(3):822–829
36. McElhinney DB, Krantz ID, Bason L, Piccoli DA, Emerick KM, Spinner NB, Goldmuntz E (2002) Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation 106(20):2567–2574
37. Kamath BM, Bauer RC, Loomes KM, Chao G, Gerfen J, Hutchinson A, Hardikar W, Hirschfeld G, Jara P, Krantz ID, Lapunzina P, Leonard L, Ng VL, Hoang PL, Piccoli DA, Spinner NB (2012) NOTCH2 mutations in Alagille syndrome. J Med Genet 49(2):138–144
38. McDaniel R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB (2006) NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 79(1):169–173
39. Xue Y, Gao X, Lindsell CE, Norton CR, Chang B, Hicks C, Gendron-Maguire M, Rand EB, Weimaster G, Gridley T (1999) Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet 8(5):723–730
40. McEricht B, Lozier J, Gridley T (2002) A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 129(4):1075–1082
41. McKellar SH, Tester DJ, Yagubyan M, Majumdar R, Ackerman MJ, Sundt TM III (2007) Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. J Thorac Cardiovasc Surg 134(2):290–296
42. McBride KL, Riley MF, Zender SM, Fitzgerald-Butt SM, Tovbin JA, Belmont JW, Cole SE (2008) NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling. Hum Mol Genet 17(18):2886–2893
43. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D (2005) Mutations in NOTCH1 cause aortic valve disease. Nature 437(7056):270–274
44. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, Aranda S, Palomo S, McCormick F, Izpisua-Belmonte JC, de la Pompa JL (2004) Notch promotes epithelial-mesenchymal transition during cardiac development and oncocgenic transformation. Genes Dev 18(1):99–115
45. Wang Y, Wu B, Chamberlain AA, Lui W, Koirala P, Susztak K, Klein D, Taylor V, Zhou B (2013) Endocardial to myocardial notch-wnt-bmp axis regulates early heart valve development. PLoS ONE 8(4):e60244
46. Luna-Zurita L, Prados B, Grego-Bessa J, Luxan G, del Monte G, Benguria A, Adams RH, Perez-Pomares JM, de la Pompa JL (2010) Integration of a Notch-dependent mesenchymal gene program and BMP2-driven cell invasiveness regulates murine cardiac valve formation. J Clin Invest 120(10):3493–3507
47. Bosse K, Hans CP, Zhao N, Koenig SN, Huang N, Guggilam P, Garg V, Klein D, Taylor V, Zhou B (2013) Endocardial to myocardial notch-wnt-bmp axis regulates early heart valve development. PLoS ONE 8(4):e60244
48. Luna-Zurita L, Prados B, Grego-Bessa J, Luxan G, del Monte G, Benguria A, Adams RH, Perez-Pomares JM, de la Pompa JL (2010) Integration of a Notch-dependent mesenchymal gene program and BMP2-driven cell invasiveness regulates murine cardiac valve formation. J Clin Invest 120(10):3493–3507
53. Sznajer Y, Keren B, Baumann C, Pereira S, Alberti C, Elion J, Cave H, Verloes A (2007) The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene. Pediatrics 119(6):e1325–e1331

54. Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B (1999) Congenital heart lesions in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 135(6):703–706

55. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kali-das K, Patton MA, Kucherlapati RS, Gelb BD (2001) Mutations in PTPN11 encoding the protein tyrosine phosphatase SHP-2 cause Noonan syndrome. Nat Genet 29(4):465–468

56. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillelssen-Kaebach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38(3):294–296

57. Schubbert S, Zenger S, Rowe SL, Boll S, Klein C, Bollag G, Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, West B, Zhang KY, Sromers M, Rauch A, Niesmeyer CM, Shannon K, Kratzen PC (2006) Germline KRAS mutations cause Noonan syndrome. Nat Genet 38(3):331–336

58. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sorkozy A, Pandit B, Sarkozy A, Digilio A, Tartaglia M, Gelb BD (2007) Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39(1):70–74

59. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin J, Tamburino AM, Neel BG, Kucheralapati RS (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39(1):70–74

60. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin J, Tamburino AM, Neel BG, Kucheralapati RS (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39(1):70–74

61. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Oka-moto N, Hennekam RC, Gillelssen-Kaebach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38(3):294–296

56. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Oka-moto N, Hennekam RC, Gillelssen-Kaebach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38(3):294–296

57. Schubbert S, Zenger S, Rowe SL, Boll S, Klein C, Bollag G, Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, West B, Zhang KY, Sromers M, Rauch A, Niesmeyer CM, Shannon K, Kratzen PC (2006) Germline KRAS mutations cause Noonan syndrome. Nat Genet 38(3):331–336

58. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sorkozy A, Pandit B, Oishi K, Martinelli S, Schackowitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Gelb BD, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD (2007) Gain-of-function SOS1 mutations cause Noonan syndrome. Nat Genet 39(1):70–74

59. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin J, Tamburino AM, Neel BG, Kucheralapati RS (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39(1):70–74

60. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin J, Tamburino AM, Neel BG, Kucheralapati RS (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39(1):70–74

61. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Oka-moto N, Hennekam RC, Gillelssen-Kaebach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38(3):294–296
an evolutionarily conserved Smad binding site. Dev Biol 244(2):257–266

80. Lien CL, Wu C, Mercer B, Webb R, Richardson JA, Olson EN (1999) Control of early cardiac-specific transcription of Nk2-5 by a GATA-dependent enhancer. Development 126(1): 75–84

81. Liberatore CM, Searcy-Schrick RD, Vincent EB, Yutzey KE (2002) Nkx-2.5 gene induction in mice is mediated by a Smad consensus regulatory region. Dev Biol 244(2):243–256

82. Pratt OW, Menon MK, Solloway MJ, Watanabe Y, Zaffran S, Bajolle F, Biben C, McBride JJ, Robertson BR, Chauvel H, Stennard FA, Wise N, Schaft D, Wolstein O, Furtado MB, Shiratori H, Chien KR, Hamada H, Black BL, Saga Y, Robertson EJ, Buckingham ME, Harvey RP (2007) An Nk2-5/Bmp2/Smad1 negative feedback loop controls heart progenitor specification and proliferation. Cell 128(5):947–959

83. Barth JL, Clark CD, Fresco VM, Knoll EP, Lee B, Argraves WS, Lee KH (2010) Jard1 is among a set of genes differentially regulated by Nkx2.5 during outflow tract morphogenesis. Dev Dyn 239(7):2024–2033

84. Durocher D, Charron F, Warren R, Schwartz RJ, Nemer M (1997) The cardiac transcription factors Nkx2–5 and GATA-4 are mutual cofactors. EMBO J 16(18):5687–5696

85. Schlesinger J, Schulte M, Grunert M, Fischer JJ, Zhang Q, Hiroi Y, Kudoh S, Monzen K, Ikeda Y, Yazaki Y, Nagai R, Cai CL, Zhou W, Yang L, Bu L, Qyang Y, Zhang X, Li X, Lu MM, Furtado MB, Solloidal C, Leiden JM (1997) GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev 11(8):1061–1072

86. Stennard FA, Costa MW, Lai D, Biben C, Wolstein O, Furtado MB, Solloidal C, Leiden JM (1997) GATA4 transcription factor genes Smad4 and Gata4 cooperatively regulate cardiac morphogenesis and disease. Cell 89(1):212–222

87. Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner DA, Gessler M, Nemer S, Seidman CE, Seidman JG (2001) A murine model of Holt–Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiovascular and cardiac and limb malformation in Holt–Oram syndrome. Nat Genet 1(5):21–29

88. Basson CT, Bachinsky DR, Lin RC, Levy T, Elkins JA, Soutsoul G, Grayzel D, Kroumposoucou E, Traill TL, Leblanc-Blacreski J, Renault B, Kucherlapati R, Seidman JG, Seidman CE (1997) Mutations in human Tbx5 (corrected) cause limb and cardiac malformation in Holt–Oram syndrome. Nat Genet 15(1):30–35

89. Singh MK, Christoffers VM, Dias J, Trowe MO, Holman DS, Harvey RP (2007) Mutations in cardiac T-box factor gene Tbx20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. Am J Hum Genet 81(2):280–291

90. Cai CL, Zhou W, Yang L, Bu L, Qyang Y, Zhang X, Li X, Lu MM, Furtado MB, Solloidal C, Leiden JM (1997) GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev 11(8):1061–1072

91. Pu WT, Ishiwata T, Juraszek AL, Ma Q, Izumo S (2004) GATA4 is a dosage-sensitive regulator of cardiac morphogenesis. Dev Biol 275(1):235–244

92. Moskowitz IP, Wang J, Peterson MA, Pu WT, Mackay JP, Wadell LB, Cole AD, Hayward C, Keogh A, Macdonald P, Griffiths L, Faktin D, Sholler GF, Zorn AM, Feneley MP, Winlaw DS, Harvey RP (2005) Mutations in cardiac T-box factor gene Tbx20 acts as a repressor during heart development, and is essential for adult heart integrity, function and adaptation. Development 132(10):2451–2462

93. Cai CL, Zhou W, Yang L, Bu L, Qyang Y, Zhang X, Li X, Rosenfeld MG, Chen J, Evans S (2005) T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development 132(10):2475–2487

94. Cai CL, Nomura-Kitabayashi A, Cai W, Van I, Christoffers VM, Cai CL (2011) Myocardial Tbx20 regulates early atrioventricular canal formation and endocardial epithelial-mesenchymal transition via Bmp2. Dev Biol 360(2):381–390

95. Hammer S, Toenjes M, Lange M, Fischer JJ, Dimmel K, Mebus S, Grimm CH, Hetzer R, Berger F, Sperlir S (2008)
Characterization of TBX20 in human hearts and its regulation by TFAP2B. J Cell Biochem 104(3):1022–1033

Satoda M, Zhao F, Diaz GA, Burn J, Goodship J, Davidson HR, Pierport ME, Gelb BD (2000) Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus. Nat Genet 25(1):42–46

Chen YW, Zhao W, Zhang ZF, Fu Q, Shen J, Zhang Z, Ji W, Wang J, Li F (2011) Familial nonsyndromic patent ductus arteriosus caused by mutations in TFAP2B. Pediatr Cardiol 32(7):958–965

Khettyar M, Syrris P, Tinworth L, Abushaban L, Carter N (2008) Novel TFAP2B mutation in nonsyndromic patent ductus arteriosus. Genet Test 12(3):457–459

Zhang F, Bosserhoff AK, Buettner R, Moser M (2011) A heart-hand syndrome gene: Ttaph2 plays a critical role in the development and remodeling of mouse ductus arteriosus and limb patterning. PLoS One 6(7):e22908

Braganca J, Swingler T, Marques FI, Jones T, Eloranta JJ, Hurst HC, Shioda T, Bhattacharya S (2002) Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem 277(10):8559–8565

Braganca J, Eloranta JJ, Bamforth SD, Ibbit JC, Hurst HC, Bhattacharya S (2003) Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2. J Biol Chem 278(18):16021–16029

Petrij F, Giles RH, Daumerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ (1995) Rubinstein–Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376(6538):348–351

Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist R, White P, Lougher LH, Towbin JA, Craigen WJ, Neish SR, Lin AE, Belmont JW, McPherson JD, Gibbs RA, white DJ (2006) Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome: mutations in both AP-2 transcription factors, p300/CReB-binding protein, and CITeD2. J Biol Chem 278(18):16021–16029

Bokenkamp R, DeRuiter MC, van Munsteren C, Gittenberger-de-Groot AC (2010) Insights into the pathogenesis and genetic background of patency of the ductus arteriosus. Neontology 98(1):6–17

Sun H, Jansen J, Jansen GM, van Breda, Van den Bosch T, Ploos van Amstel HG, Bagnasco M, Van den Berghe H, Shilatifard A (2008) Molecular implementation and physiological roles of histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol 20(3):341–348

Lalani SR, Saftullah AM, Fernbach SD, Harutyunyan KG, Thaller C, Peterson LE, McPherson JD, Gibbs RA, White LD, Hefner M, Davenport SL, Graham JM, Bacino CA, Glass NL, Towbin JA, Craigen WJ, Neish SR, Lin AE, Belmont JW (2006) Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome and genotype-phenotype correlation. J Am Med Genet 100(4):269–274

Ng SB, Bigham AW, Buckingham JJ, Hannibal MC, McMillin MJ, Gildersleeve HI, Bigham AW, Tabor HK, Mefford HC, Cook J, Yoshuia K, Matsumoto K, Matsumoto N, Miyake N, Tonoki H, Naritomi K, Kaname T, Nagai T, Ohashi H, Kuroswa K, Hou JW, Ohta T, Liang D, Sudo A, Morris CA, Banka S, Black GC, Clayton-Smith J, Nickerson DA, Zackai EH, Shaikh TH, Donnai D, Niikawa N, Shendure J, Bamshad MJ (2011) Spectrum of MLT2 (ALR) mutations in 110 cases of Kabuki syndrome. Am J Med Genet A 155A(7):1511–1516

Digilio MC, Marino B, Toscano A, Giannotti A, Dallapiccola B (2001) Congenital heart defects in Kabuki syndrome. Am J Med Genet 100(4):269–274

Ng SB, Bigham AW, Buckingham JJ, Hannibal MC, McMillin MJ, Gildersleeve HI, Beck AE, Tabor HK, Cooper GM, Mefford HC, Lee C, Turner EH, Smith JD, Rieder MJ, Yoshiura K, Matsumoto N, Ohta T, Niikawa N, Nickerson DA, Bamshad MJ, Shendure J (2010) Exome sequencing identifies MLT2 mutations as a cause of Kabuki syndrome. Nat Genet 42(9):790–793

Shilatifard A (2008) Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol 20(3):341–348

Lalani SR, Saftullah AM, Fernbach SD, Harutyunyan KG, Thaller C, Peterson LE, McPherson JD, Gibbs RA, White LD, Hefner M, Davenport SL, Graham JM, Bacino CA, Glass NL, Towbin JA, Craigen WJ, Neish SR, Lin AE, Belmont JW (2006) Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome and genotype-phenotype correlation. J Am Med Genet 100(4):269–274

Ng SB, Bigham AW, Buckingham JJ, Hannibal MC, McMillin MJ, Gildersleeve HI, Beck AE, Tabor HK, Cooper GM, Mefford HC, Lee C, Turner EH, Smith JD, Rieder MJ, Yoshuia K, Matsumoto K, Ohta T, Niikawa N, Nickerson DA, Bamshad MJ, Shendure J (2010) Exome sequencing identifies MLT2 mutations as a cause of Kabuki syndrome. Nat Genet 42(9):790–793

Shilatifard A (2008) Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol 20(3):341–348

Lalani SR, Saftullah AM, Fernbach SD, Harutyunyan KG, Thaller C, Peterson LE, McPherson JD, Gibbs RA, White LD, Hefner M, Davenport SL, Graham JM, Bacino CA, Glass Nl, Towbin JA, Craigen WJ, Neish SR, Lin AE, Belmont JW (2006) Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome and genotype-phenotype correlation. J Am Med Genet 100(4):269–274
138. Schnetz MP, Bartels CF, Shastri K, Balasubramanian D, Zentner wyse RK, al-Mahdawi S, Burn J, Blake K (1993) Congenital heart disease in CHARGE association. Pediatr Cardiol 14(2):75–81

137. Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, de Vries BB, Janssen IM, van der Vliet WA, Huys EH, de Jong PJ, Hamel BC, Schoennakers EF, Brunner HG, Veltman JA, van Kessel AG (2004) Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 36(9):955–957

136. Embleton ND, Wyllie JP, Wright MJ, Burn J, Hunter S (1996) Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Lin HY, Lin SP, Chen YJ, Hung HY, Kao HA, Hsu CH, Chen Mazzanti L, Cacciari E (1998) Congenital heart disease in patients with Turner’s syndrome. Italian study group for Turner syndrome region causes aortic arch defects in mice. Nature 410(6824):97–101

135. Jerome LA, Papaioannou VE (2001) DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. Nat Genet 27(3):286–291

134. Lindsey EA, Vitelli F, Su H, Morishima M, Huynh T, Prampram T, Juricic V, Ogurumiu G, Sutherland HF, Scambler PJ, Bradley A, Baldini A (2001) Tbx1 haploinsufficiency in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 410(6824):97–101

133. Xu H, Morishima M, Wylie JN, Schwarz RJ, Bruneau BG, Lindsay EA, Baldini A (2004) Tbx1 has a dual role in the morphogenesis of the cardiac outflow tract. Development 131(13):3217–3227

132. Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, Minoshima S, Ichida F, Joo K, Kimura M, Imamura S, Kama-tani N, Momma K, Takao A, Nakazaka M, Shimizu N, Mat-suoka R (2003) Role of Tbx1 in human del22q11.2 syndrome. Lancet 362(9393):1366–1373

131. Zweier C, Sticht H, Aydin-Yaylagul I, Campbell CE, Rauch A (2007) Human Tbx1 missense mutations cause gain of function resulting in the same phenotype as 22q11.2 deletions. Am J Hum Genet 80(3):510–517

130. Funk B, Epstein JA, Kochilas LK, Lu MM, Pandita RK, Liao J, Baumerdistel R, Schuler T, Schorle H, Brown MC, Adams J, Morrow BE (2001) Mice overexpressing genes from the 22q11 region deleted in velocardio-facial syndrome/DiGeorge syndrome have middle and inner ear defects. Hum Mol Genet 10(22):2549–2556

129. Liao J, Kochilas L, Nowotschin S, Arnold JS, Aggarwal VS, Epstein JA, Brown MC, Adams J, Morrow BE (2004) Full spectrum of malformations in velocardio-facial syndrome/DiGeorge syndrome mouse models by altering Tbx1 dosage. Hum Mol Genet 13(15):1577–1585

128. Garcia-Minaur S, Fantes J, Murray RS, Porteous ME, Strain L, Burns JE, Stephen J, Warner JP (2002) A novel atypical 22q11.2 deletion in father and son. J Med Genet 39(10):e62

127. Rech A, Zink S, Zweier C, Thielt CT, Koch A, Rauch R, Laszcorz J, Hoffmeier U, Weyand M, Singer H, Holbeck M (2005) Systematic assessment of atypical deletions reveals genotype-phenotype correlation in 22q11.2. J Med Genet 42(11):871–876

126. Sorensen KM, El-Segaiuer M, Fernlund E, Errami A, Bouvagnet P, Nehme N, Steensberg J, Hjortdal V, Soller M, Behjati M, Werge T, Kirkhoff M, Schouten J, Tommerup N, Andersen PS, Larsen LA (2012) Screening of congenital heart disease patients using multiplex ligation-dependent probe amplification: early diagnosis of syndromic patients. Am J Med Genet A 158A(4):720–725

125. Gorsli DL, Fantes J, Tara D, Druker BJ, Imamoto A (2001) Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nat Genet 27(3):293–298

124. Gorsli DL, Duester G, Papaioannou VE, Imamoto A (2006) Dose-dependent interaction of Tbx1 and Crkl and locally aberrant RA signaling in a model of del22q11 syndrome. Dev Cell 10(1):81–92

123. Moon AM, Gorsli DL, Seo JH, Li L, Hammond J, Talbot A, Imamoto A (2006) Crkl deficiency disrupts Fgfl8 signaling in a mouse model of 22q11 deletion syndromes. Dev Cell 10(1):71–80
166. Liao J, Aggarwal VS, Nowotschin S, Bondarev A, Lipner S, Morrow BE (2008) Identification of downstream genetic pathways of Tbx1 in the second heart field. Dev Biol 316(2):524–537

167. Roberts C, Ivins SM, James CT, Scambler PJ (2006) Cyp26 genes a1, b1 and c1 are down-regulated in Tbx1 null mice and inhibition of Cyp26 enzyme function produces a phe- nocopy of DiGeorge Syndrome in the chick. Hum Mol Genet 15(23):3394–3410

168. Ivins S, van Lammers BK, Roberts C, James C, Lindsay E, Baldini A, Ataliotis P, Scambler PJ (2005) Microarray analysis detects differentially expressed genes in the pharyngeal region of mice lacking Tbx1. Dev Biol 285(2):554–569

169. Roberts C, Ivins SM, James CT, Scambler PJ (2005) Retinoic acid down-regulates Tbx1 expression in vivo and in vitro. Dev Dyn 232(4):928–938

170. Garg V, Yamagishi C, Hu T, Katrihia IS, Yamagishi H, Srivastava D (2001) Tbx1, a DiGeorge syndrome candidate gene, is regulated by sonic hedgehog during pharyngeal arch development. Dev Biol 235(1):62–73

171. Yamagishi H, Maeda J, Hu T, McNally J, Conway SJ, Kume T, Meyers EN, Yamagishi C, Srivastava D (2003) Tbx1 is regulated by tissue-specific forkhead proteins through a common Sonic hedgehog-responsive enhancer. Genes Dev 17(2):269–281

172. Hu T, Yamagishi H, Maeda J, McNally J, Yamagishi C, Srivastava D (2004) Tbx1 regulates fibroblast growth factors in the anterior heart field through a reinforcing autoregulatory loop involving forkhead transcription factors. Development 131(21):5491–5502

173. Vitelli F, Taddei I, Morishima M, Meyers EN, Lindsay E A, Baldini A (2002) A genetic link between Tbx1 and fibroblast growth factor signaling. Development 129(19):4605–4611

174. Guo C, Sun Y, Zhou B, Adam RM, Li X, Pu WT, Morrow BE, Moon A, Li X (2011) A Tbx1-Six1-Eya1-Fgfl8 genetic pathway controls mammalian cardiovascular and craniofacial morphogenesis. J Clin Invest 121(4):1585–1595

175. Fulcoli FG, Huynh T, Scambler PJ, Baldini A (2009) Tbx1 regulates the BMP-Smad1 pathway in a transcription independent manner. PLoS One 4(6):e6049

176. Ewart AK, Morris CA, Atkinson D, Jin W, Sternes K, Spallone P, Stock AD, Leppert M, Keating MT (1993) Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet 5(1):11–16

177. Lowery MC, Morris CA, Ewart A, Brothman LJ, Zhu XL, Leonard CO, Carey JC, Keating M, Brothman AR (1995) Strong correlation of elastin deletions, detected by FISH, with Williams syndrome: evaluation of 235 patients. Am J Hum Genet 57(1):49–53

178. Perez Jurado LA, Peoples R, Kaplan P, Hamel BC, Francke U (1996) Molecular definition of the chromosome 7 deletion in Williams syndrome and parent-of-origin effects on growth. Am J Hum Genet 59(4):781–792

179. Poher BR (2010) Williams–Beuren syndrome. N Engl J Med 362(3):239–252

180. del Pasqua A, Rinelli G, Toscano A, Iacobelli R, Digilio C, Marino B, Saffirio C, Mondillo S, Pasquini L, Sanders SP, de Zorzi A (2009) New findings concerning cardiovascular manifestations emerging from long-term follow-up of 150 patients with the Williams–Beuren Syndrome. Cardiol Young 19(6):563–567

181. Eronen M, Peippo M, Hiippala A, Raatikka M, Arvio M, Johansson R, Kakkonen M (2002) Cardiovascular manifestations in 75 patients with Williams syndrome. J Med Genet 39(8):554–558

182. Frangiskakis JM, Ewart AK, Morris CA, Mervis CB, Bertrand J, Robinson BF, Klein BP, Ensing GJ, Everett LA, Green ED, Proschel C, Gutowski NJ, Noble M, Atkinson DL, Odelberg SJ, Keating MT (1996) Lim-kinase1 hemizygosity implicated in impaired visuospatial constructive cognition. Cell 86(1):59–69

183. Tassabehji M, Metcalfe K, Karmiloff-Smith A, Carette MJ, Grant J, Dennis N, Reardon W, Splitt M, Read AP, Donnai D (1999) Williams syndrome: use of chromosomal microdeletions as a tool to dissect cognitive and physical phenotypes. Am J Hum Genet 64(1):118–125

184. Li DY, Toland AE, Boak BB, Atkinson DL, Ensing GJ, Morris CA, Keating MT (1997) Elastin point mutations cause an obstructive vascular disease, supravalvular aortic stenosis. Hum Mol Genet 6(7):1021–1028

185. Metcalfe K, Rucka AK, Smoot L, Hofstadler G, Tuzler G, Donsky Y, Vatanza D, Yamagishi C, Srivastava D (2001) Tbx1, a DiGeorge syndrome candidate gene, is regulated by sonic hedgehog during pharyngeal arch development. Dev Biol 251(1):62–73

186. Yoshimura K, Kitagawa H, Fujiki R, Tanabe M, Takezawa S, Takada I, Yamaoka I, Yonezawa M, Kondo T, Furutani Y, Yagi H, Yoshinaga S, Masuda T, Fukuda T, Yamamoto Y, Ebita H, Li DY, Matsuo R, Takeuchi JK, Matsumoto T, Kato S (2009) Distinct function of 2 chromatin remodeling complexes that share a common subunit, Williams syndrome transcription factor (WSTF). Proc Natl Acad Sci USA 106(23):9280–9285

187. Kitagawa H, Fujiki R, Yoshimura K, Mezaki Y, Uematsu Y, Matsui S, Ogawa S, Unno K, Okubo M, Tokita A, Nakagawa T, Ito T, Ishimi Y, Nagasawa H, Matsumoto T, Yanagisawa J, Kato S (2003) The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 113(7):905–917

188. Bozhenok L, Wade PA, Varga-Weisz P (2002) WSTF-ISW1 chromatin remodeling complex targets heterochromatic replication foci. EMBO J 21(9):2231–2241

189. Cavellan E, Asp P, Percipalle P, Farrants AK (2006) The WSTF-SNP2 h chromatin remodeling complex interacts with several nuclear proteins in transcription. J Biol Chem 281(14):16264–16271

190. Poot RA, Bozhenok L, van den Berg DL, Steffensen S, Ferreira P, Grimaldi M, Gilbert N, Ferreira J, Varga-Weisz PD (2004) The Williams syndrome transcription factor interacts with PCNA to target chromatin remodelling by ISWI to replication foci. Nat Cell Biol 6(12):1236–1244

191. Maas NM, Van BG, Hannes F, Thienpont B, Sanlaville D, Kok K, Midro A, Andrieux J, Anderlid BM, Schoumans J, Hordijk D, Tassabehji M (2000) Elastin: mutational spectrum in supravalvular aortic stenosis. Hum Genet A 149A(8):1661–1677
Gourdie RG, Severs NJ, Green CR, Rothery S, Germroth P, Kirchhoff S, Nelles e, Hagendorff A, Kruger O, Traub O, Willemsen MH, Vulto-van Silfhout AT, Nillesen WM, Wisinski-Lindhout WM, van Bokhoven H, Philip N, Berry-Kravis EM, Kini U, van Ravenswaaij-Arts CM, Delle CB, Innes AM, Hougé H, Kosonen T, Cremer K, Fannemel M, Stray-Pedersen A, Reardon W, Ignatius J, Lachlan K, Bircher C, Helderem van den Enden PT, Mastebroek M, Cohn-Hokke PL, Yntema HG, Drutat S, Kleefstra T (2012) Update on Kleefstra syndrome. Mol Syndromol 2(3–5):202–212

Tachibana M, Ueda J, Fukuda M, Takeda N, Iwata H, Sakahama T, Kodama T, Hamakubo T, Shinkai Y (2005) Histone methyltransferases G9a and G9p form heterocomplexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev 19(7):815–826

Duborg C, Sanlaville D, Doco-Fenzy M, Le CC, Missirian C, Jaillard S, Schluth-Bolard C, Landaia E, Boute O, Philip N, Touain A, David A, Edery P, Moncla A, Martin-Coingrand D, Vincent-Delorme C, Mortemousse I, Duban-Bedu B, Drutat S, Beri M, Mosser J, Odent S, David V, Andrieux J (2011) Clinical and molecular characterization of 17q21.31 microdeletion syndrome in 14 French patients with mental retardation. Eur J Med Genet 54(2):144–151

Koolen DA, Sharp AJ, Hurst JA, Firth HV, Knight SJ, Goldberg A, Saugier-Veber P, Pfundt R, Vissers LE, Destree A, Grisart B, Rooms L, Van der Aa N, Field M, Hackett A, Bell K, Nowaczyk M, Mancini GM, Podgidge PJ, Schwartz CE, Rossi E, De Gregori M, Antonacci-Fulton LL, McLellan MD, Garrett JM, Wetichert MA, Miner TL, Crosby S, Ciccone R, Willat T, Rauch A, Zeker M, Aradnya S, Manning MA, Strom TM, Wagenstein J, Krepischi-Santos AC, Vianna-Morgante AM, Rosenberg C, Price SM, Stewart H, Shaw-Smith C, Brunner HG, Willek AO, Veltman JA, Zuffardi O, Eichler EE, de Vries BB (2008) Clinical and molecular delineation of the 17q21.31 microdeletion syndrome. J Med Genet 45(11):710–720

Koolen DA, Kramer JM, Neveing K, Nillesen WM, Mooer-Barton HL, Elsmieke FV, Toutain A, Amiel J, Malan V, Tsai AC, Cheung SW, Gilissen C, Verwilghen EF, Martens S, Feuth T, Bongers EM, de Vries P, Scheffer H, Vissers LE, de Brouwer AP, Brunner HG, Veltman JA, Schenck A, Yntema HG, de Vries BB (2012) Mutations in the chromatin modifier gene KANSL1 cause the 17q21.31 microdeletion syndrome. Nat Genet 44(6):639–641

Zollino M, Orteschi D, Murdolo M, Lattante S, Battaggia D, Stefanic F, Mercuri E, Chiaruzzi P, Neri G, Marangi G (2012) Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome phenotype. Nat Genet 44(6):636–638

Laverty C, Lucci J, Akhtar A (2010) The MLB complex: X chromosome and beyond.Curr Opin Genet Dev 20(2):171–178

Smith ER, Nayrou C, Huang R, Lane WS, Cote J, Lucchesi JC (2005) A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol 25(21):9175–9188

Ballyf BC, Theisen A, Rosenfeld JA, Traylor RN, Gastier-Foster J, Thrash DL, Astbury C, Bartholomew D, McBride KL, Pyatt RE, Shan K, Smith WE, Banks V, Gallentine WB, Brock P, Rudd MM, Adam MP, Keene JA, Phillips JA, III, Pfitznerhauer JP, Gowans GC, Stankiewicz P, Beijani BA, Shafer LG (2010) Identification of a recurrent microdeletion at 17q23.1q23.2 flanked by segmental duplications associated with heart defects and limb abnormalities. Am J Hum Genet 86(3):454–461
217. Harrelson Z, Kelly RG, Goldin SN, Gibson-Brown JJ, Bollag RJ, Silver LM, Papaioanou VE (2004) Tbx2 is essential for patterning the atrioventricular canal and for morphogenesis of the outflow tract during heart development. Development 131(20):5041–5052

218. Christoffels VM, Hoogaars WM, Tassari A, Clout DE, Moorman AF, Campione M (2004) T-box transcription factor Tbx2 represses differentiation and formation of the cardiac chambers. Dev Dyn 229(4):763–770

219. Habets PE, Moorman AF, Clout DE, van Roon MA, Lingbeek M, Christoffels vM, Hoogaars wM, Tessari A, Clout DE, Moor -Molecular genetics of CHD

220. Breckpot J, Thiennon B, Arens Y, Tranchevent LC, Vermeesch JR, Moreau Y, Gewillig M, Devriendt K (2010) Array comparative genomic hybridization as a diagnostic tool for syndromic heart defects. J Pediatr 156(5):810–817

221. Breckpot J, Thiennon B, Arens Y, Tranchevent LC, Vermeesch JR, Moreau Y, Gewillig M, Devriendt K (2011) Challenges of interpreting copy number variation in syndromic and non-syndromic congenital heart defects. CytoGenet Genome Res 135(3–4):251–259

222. Erdogan F, Larsen LA, Zhang L, Tumer Z, Tommerup N, Chen W, Jacobsen JR, Schubert M, Jurkats J, Tszschach A, Ropers HH, Ullmann R (2008) High frequency of submicroscopic genomic aberrations detected using tiling path array comparative genome hybridisation in patients with isolated congenital heart disease. J Med Genet 45(11):704–709

223. Fakhro KA, Choi M, ware SM, Belmont Jw, Towbin JA, Erdogan F, Larsen LA, Zhang L, Tumer Z, Tommerup N, Chen W, Jacobsen JR, Schubert M, Jurkats J, Tszschach A, Ropers HH, Ullmann R (2004) T-box transcription factor Tbx2 represses differentiation and formation of the cardiac chambers. Development 131(20):5041–5052

224. Silver LM, Papaioannou ve (2004) Tbx2 is essential for pattern-formation. Genes Dev 16(10):1234–1246

225. Tomita-Mitchell A, Mahanke DK, Struble CA, Tuffnell ME, Stamm KD, Hidestrand M, Harris SE, Goetsch MA, Simpson PM, Bick DP, Broeckel U, Pelech AN, Tweddel JS, Mitchell ME (2012) Human gene copy number spectra analysis in congenital heart malformations. Physiol Genomics 44(9):518–541

226. Aerts S, Lambrechts D, Maity S, Van Loo P, Coensens B, De Smet F, Tranchevent LC, De Moor B, Marynen P, Hassan B, Carmeliwiet P, Moreau Y (2006) Gene prioritization through genomic data fusion. Nat Biotechnol 24(5):537–544

227. Thiennon B, Mertens L, de Ravel T, Eyskens B, Boshoff D, Maas N, Frys JP, Gewillig M, Vermeesch JR, Devriendt K (2007) Submicroscopic chromosomal imbalances detected by array-CGH are a frequent cause of congenital heart defects in selected patients. Eur Heart J 28(22):2778–2784

228. Lage K, Greenway SC, Rosenfeld J, Jakubowicz J, Zanotti S, Carrera J, Tommerup N, Brunak S, Ballif BC, Shafer LG, Donahoe PK, Daly MJ, Seidman CE, Seidman JG, Larsen LA (2010) Haploinsufficiency of TAB2 causes congenital heart defects in humans. Am J Hum Genet 86(6):839–849

229. Trudeau H, Hamada H (2006) The left-right axis in the mouse: from origin to morphology. Development 133(11):2095–2104

230. Lage K, Greenway SC, Rosenfeld J, Jakubowicz J, Zanotti S, Carrera J, Tommerup N, Brunak S, Ballif BC, Shafer LG, Donahoe PK, Daly MJ, Seidman CE, Seidman JG, Larsen LA (2012) Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development. Proc Natl Acad Sci USA 109(35):14035–14040

231. McBride KL, Zender GA, Fitzgerald-Butt SM, Koehler D, Meneses-Diaz A, Fernbach A, Lee K, Towbin JA, Leal S, Belmont JW (2009) Linkage analysis of left ventricular outflow tract malformations (aortic valve stenosis, coarctation of the aorta, and hypoplastic left heart syndrome). Eur J Hum Genet 17(6):811–819

232. Winston JB, Erlich JM, Green CA, Aluko A, Kaiser KA, Take-matsumi M, Barlow RS, Suresh OA, Laplage MJ, Jans LL, Jay PY (2010) Heterogeneity of genetic modifiers ensures normal cardiac development. Circulation 121(11):1313–1321

233. Talkowski ME, Rosenfeld JA, Blumenthal I, Pillailamarrvi J, Chang C, Heibut A, Ernst C, Hanscom C, Rossin L, Lindgren AM, Pereira S, Rudferfer D, Kirby A, Ripke S, Harris DJ, Lee JH, Ha K, Kim HG, Solomon BD, Groppman AL, Lucente D,
Sims K, Ohsumi TK, Borowsky ML, Loranger S, Quade B, Lage K, Miles J, Wu BL, Shen Y, Neale B, Shaffer LG, Daly MJ, Morton CC, Gusella JF (2012) Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 149(3):525–537

242. Hu Z, Shi Y, Mo X, Xu J, Zhao B, Lin Y, Yang S, Xu Z, Dai J, Pan S, Da M, Wang X, Qian B, Wen Y, Wen J, Xing J, Guo X, Xia Y, Ma H, Jin G, Yu S, Liu J, Zhou Z, Wang X, Chen Y, Sha J, Shen H (2013) A genome-wide association study identifies two risk loci for congenital heart malformations in Han Chinese populations. Nat Genet 45(7):818–821

243. Cordell HJ, Bentham J, Topf A, Zelenika D, Heath S, Mamassoula C, Cosgrove C, Blue G, Granados-Riveron J, Setchfield K, Thornborough C, Breqkpot J, Soemedi R, Martin R, Rahman T, Hall D, van Engelen K, Moorman AF, Zwinderman AH, Barnett P, Koopmann TT, Adriaenssens VE, Varro A, George AL, Jr, Dos RC, Bishopric NH, Bezzina CR, Sullivan J, Gwili M, Bu’Lock FA, Winlaw D, Bhattacharya S, Devriendt K, Brook JD, Mulder BJ, Mital S, Postma AV, Lathrop GM, Farrall M, Goodship JA, Keavney BD (2013) Genome-wide association study of multiple congenital heart disease phenotypes identifies a susceptibility locus for atrial septal defect at chromosome 4p16. Nat Genet 45(7):822–824

244. Cordell HJ, Topf A, Mamasoula C, Postma AV, Bentham J, Zelenika D, Heath S, Blue G, Cosgrove C, Granados RJ, Daray R, Soemedi R, Wilson JJ, Ayers KL, Rahman TJ, Hall D, Mulder BJ, Zwinderman AH, van Engelen K, Brook JD, Setchfield K, Bu’Lock FA, Thornborough C, Sullivan J, Stuart AG, Parsons J, Bhattacharya S, Winlaw D, Mital S, Gwili M, Breckpot J, Devriendt K, Moorman AF, Rauch A, Lathrop GM, Keavney BD, Goodship JA (2013) Genome-wide association study identifies loci on 12q24 and 13q32 associated with tetralogy of Fallot. Hum Mol Genet 22(7):1473–1481

245. Tian Y, Yuan L, Goss AM, Wang T, Yang J, Lepore JJ, Zhou D, Kohlhase J, Heinrich M, Schubert L, Liebers M, Kispert J, Heathcote K, Braybrook C, Abushaban L, Guy M, Khetyar M, Muncke N, Jung C, Rudiger H, Ulmer H, Roeth R, Hubert A, Goldmuntz E, Driscoll D, Goodship J, Schon K, Rappl G (2003) Missense mutations and gene interruption in PROSIT240, a novel TRAP240-like gene, in patients with congenital heart defects. Hum Mutat 33(4):720–727

246. Maitra M, Koening SN, Srivastava D, Garg V (2010) Identification of GATA6 sequence variants in patients with congenital heart defects. Pediatr Res 68(4):281–285

247. Cheng Z, Wang J, Su D, Pan H, Huang G, Li X, Li Z, Shen A, Xie Y, Wang B, Ma X (2011) Two novel mutations of the IRX4 gene in patients with congenital heart disease. Hum Genet 130(5):657–662

248. Muncke N, Jung C, Rudiger H, Ulmer H, Roeth R, Hubert A, Goldmuntz E, Driscoll D, Goodship J, Schon K, Rappl G (2003) Missense mutations and gene interruption in PROSIT240, a novel TRAP240-like gene, in patients with congenital heart defect (transposition of the great arteries). Circulation 108(23):2843–2850

249. Heathcote K, Braybrook C, Abushaban L, Guy M, Khetyar M, Patton MA, Carter ND, Scambler PJ, Syrris P (2005) Common arterial trunk associated with a homeodomain mutation of NKX2.6. Hum Mol Genet 14(5):585–593

250. Kohlhase J, Heinrich M, Schubert L, Liebers M, Kispert A, Laccoce F, Turnpenny P, Winter RM, Reardon W (2002) Okihiro syndrome is caused by SALL4 mutations. Hum Mol Genet 11(23):2979–2987

251. Al-Baradie R, Yamada K, St HC, Chan WM, Andrews C, McIntosh N, Nakano M, Martonyi EJ, Raymond WR, Okumura S, Okihiro MM, Engle EC (2002) Duane radial ray syndrome (Okihiro syndrome) maps to 2q13 and results from mutations in SALL4, a new member of the SALL family. Am J Hum Genet 71(5):1195–1199

252. Wang B, Li L, Xie X, Wang J, Yan J, Mu Y, Ma X (2010) Genetic variation of SALL-Like 4 (SALL4) in ventricular septal defect. Int J Cardiol 145(2):224–226

253. Pizzuti A, Sarkozy A, Newton AL, Conti E, Flex E, Digilio MC, Amati F, Gianni D, Tondi C, Marino B, Crossley M, Dallapiccola B (2003) Mutations of ZFPM2/FOG2 gene in sporadic cases of tetralogy of Fallot. Hum Mutat 22(5):372–377

254. Nemier G, Fadlalah F, Usta J, Nemier M, Dbaibo G, Obeid M, Bitar F (2006) A novel mutation in the GATA4 gene in patients with Tetralogy of Fallot. Hum Mutat 27(3):293–294

255. Smith KA, Joziasse IC, Chocron S, van Dinther M, Guryev V, Verhoeven MC, Rehm H, van der Smagt J, Doevendans PA, Cuppen E, Mulder BJ, Ten DP, Bakkers J (2009) Dominant-negative ALK2 allele associates with congenital heart defects. Circulation 119(24):3062–3069

256. Bleyl SB, Sajioh Y, Bax NA, de Groot Gittenberger AC, Wisse AHJ, Chapman SC, Hunter J, Shiratori H, Hamada H, Yamada S, Shiota K, Klevner SE, Leppert MF, Schoenwolf GC (2010) Dysfunction of the PDGFRA gene causes inflow tract anomalies including TAPVR: integrating evidence from human genetics and model organisms. Hum Mol Genet 19(7):1286–1301

257. Aoki Y, Niihori T, Banjo T, Okamoto M, Mizuno S, Kurosawa K, Ogata T, Takada F, Yano M, Ando T, Hoshika T, Barnett C, Ohashi H, Kawame H, Hasegawa T, Okutani T, Nagashima T, Hasegawa S, Funayama R, Nagashima T, Nakayama K, Inoue SI, Watanabe Y, Ogura T, Matsuura Y (2013) Gain-of-Function Mutations in RIT1 Cause Noonan Syndrome, a RAS/MAPK Pathway Syndrome. Am J Hum Genet 93(1):173–180

258. Tan HL, Glen E, Topf A, Hall D, O’Sullivan JJ, Sneddon L, Wren C, Avery P, Lewis RJ, Ten DP, Arthur HM, Goodship JA, Keavney BD (2012) Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation. Hum Mutat 33(4):720–727

259. Robinson SW, Morris CD, Goldmuntz E, Keller MD, Jones MA, Steiner RD, Maslen CL (2003) Missense mutations in CRELD1 are associated with cardiac atrioventricular septal defects. Am J Hum Genet 72(4):1047–1052

260. Lalani SR, Ware SM, Wang X, Zapata G, Tian Q, Franco LM, Jiang Z, Bucasas K, Scott DA, Campeau PM, Hanchard N, Umana L, Cast A, Patel A, Cheung SW, McBride KL, Bray M, Craig IA, Boggs BA, Huang M, Baker MR, Hamilton S, Towbin J, Jeffries JL, Fernbach SD, Potocki L, Belmont JW (2013) MCTP2 is a dosage-sensitive gene required for cardiac outflow tract development. Hum Mol Genet (Epub ahead of print)

261. Ryan AK, Goodship JA, Wilson DI, Philip N, Levy A, Seidel H, Schuffenhauer S, Oechsler H, Belohradsky B, Prieur M, Aurias A, Raymond FL, Clayton-Smith J, Hatchwell E, McKeeown C, Beemer FA, Dallapiccola B, Novelli G, Hurst JA, Ignatiu J, Green AJ, Winter RM, Brudon L, Brumond-Nielsen K, Scambler PJ (1997) Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a european collaborative study. J Med Genet 34(10):798–804

262. Battaglia A, Hoyne HM, Dallapiccola B, Zackai E, Hudsins L, Donald-McGinn D, Bahl-Buisson N, Romano C, Williams CA, Bralley LL, Zuberi SM, Carey JC (2008) Further delineation of deletion 1p36 syndrome in 60 patients: a recognizable phenotype and common cause of developmental delay and mental retardation. Pediatrics 121(2):404–410
265. Mitter D, Chiaie BD, Ludecke HJ, Gillessen-Kaesbach G, Bohring A, Kohlhase J, Caliebe A, Siebert R, Roepeke A, Ramos-Arroyo MA, Nieva B, Menten B, Loeyes B, Mortier G, Wieczorek D (2010) Genotype-phenotype correlation in eight new patients with a deletion encompassing 2q31.1. Am J Med Genet A 152A(5):1213–1224

266. Ballif BC, Hornor SA, Jenkins E, Madan-Khetarpal S, Surti U, Jackson KE, Asamoah A, Brock PL, Gowans GC, Conway RL, Graham JM Jr, Medne L, Zakkai EH, Shaikh TK, Geoghegan J, Selzer RR, Eis PS, Bejani BA, Shaffer LG (2007) Discovery of a previously unrecognized microdeletion syndrome of 16p11.2–p12.2. Nat Genet 39(9):1071–1073

267. Grossfeld PD, Mattina T, Lai Z, Favier R, Jones KL, Cotter F, Jones C (2004) The 11q terminal deletion disorder: a prospective study of 110 cases. Am J Med Genet A 129A(1):51–61

268. Battaglia A, Filippi T, Carey JC (2008) Update on the clinical features and natural history of Wolf-Hirschhorn (4p-) syndrome: experience with 87 patients and recommendations for routine health supervision. Am J Med Genet C Semin Med Genet 148C(4):246–251

269. Girirajan S, Vlangos CN, Szomju BB, Edelman E, Trevors CD, Battaglia A, Filippi T, Carey JC (2008) Update on the clinical features and natural history of Wolf-Hirschhorn (4p-) syndrome: experience with 87 patients and recommendations for routine health supervision. Am J Med Genet C Semin Med Genet 148C(4):246–251

270. Potocki L, Shaw CJ, Stankiewicz P, Lupski JR (2003) Variability in clinical phenotype despite common chromosomal deletion in Smith–Magenis syndrome: evidence that multiple genes in 17p11.2 contribute to the clinical spectrum. Genet Med 5(7):417–427

271. Brunetti-Pierri N, Berg JS, Scaglia F, Belmont J, Bacino CA, Potocki L, Biow, Treadwell-Deering D, Carvalho CM, Eifert A, Potocki L (2009) Microduplication 22q11.2: a new chromosomal syndrome associated with mental retardation and seizures. Genet Med 87(2):219–228

272. Sharp AJ, Mefford HC, Li K, Baker C, Skinner C, Stevenson RE, Schreier RJ, Novara F, De GM, Ciccone R, Broome A, Casuga I, Wang Y, Xiao C, Barbacioru C, Gimelli G, Bernardina BD, Torniero C, Giorda R, Regan R, Murdavay V, Mansour S, Fichera M, Castiglia L, Failla P, Ventureta M, Jiang Z, Cooper GM, Knight SJ, Romano C, Zuffardi O, Chen C, Schwartz CE, Eichler EE (2008) A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat Genet 40(3):322–328

273. van Bon BW, Mefford HC, Menten B, Koolen DA, Sharp AJ, Nillesen WM, Innis JW, de Ravel TJ, Mercer CL, Fichera M, Stewart H, Connell LE, Ounap K, Lachlan K, Castle B, Van der Aa N, van Ravenswaaij C, Nobrega MA, Serra-Julhe C, Simonic L, de Leeuw N, Piundri R, Bongers EM, Baker C, Finnemore P, Huang S, Maloney VK, Crolla JA, van Kalmthout M, Elia M, Vanweweler G, Fryns JP, Janssens S, Foulds N, Reitano S, Smith K, Parkel S, Loeyes B, Woods CG, Oostra A, Speleman F, Pereira AC, Kurg A, Willatt L, Knight SJ, Vermeesch JR, Romano C, Barber JC, Mortier G, Perez-Jurado LA, Kooy F, Brunner HG, Eichler EE, Kleefstra T, de Vries BB (2009) Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome. J Med Genet 46(8):511–523

274. Thiendonk B, Bena F, Breekpot J, Philip N, Menten B, Van EH, Scalais E, Salamone JM, Fong CT, Kussmann JL, Grange JM Jr, Gorski JL, Zahir F, Yong SL, Morris MM, Gimelli S, Fryns JP, Mortier G, Friedman JM, Villard L, Bottani A, Vermeesch JR, Cheung SW, Devriendt K (2010) Duplications of the critical Rubinstein-Taybi deletion region on chromosome 16p13.3 cause a novel recognisable syndrome. J Med Genet 47(3):155–161

275. Nagamani SC, Erez A, Bader P, Lalani SR, Scott DA, Scaglia F, Plon SE, Tsai CH, Reimischel T, Roeder ER, Malphrus AD, Eng PA, Hixson PM, Kang SH, Stankiewicz P, Patel A, Cheung SW (2011) Phenotypic manifestations of copy number variation in chromosome 16p13.11. Eur J Hum Genet 19(3):280–286

276. Potocki L, Bi W, Treadwell-Deering D, Carvalho CM, Eifert A, Friedman EM, Glade D, Krull K, Lee JA, Lewis RA, Mendoza-Londono R, Robbins-Furman P, Shaw C, Shi X, Weissenberger G, Withers M, Yatsenko SA, Zackai EH, Stankiewicz P, Lupski JR (2007) Characterization of Potocki–Lupski syndrome [dup(17)(p11.2p11.2)] and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. Am J Hum Genet 80(4):633–649

277. Soler-Alfonso C, Motili KJ, Turk CL, Robbins-Furman P, Friedman EM, Zhang F, Lupski JR, Fraley JK, Potocki L (2011) Potocki–Lupski syndrome: a microduplication syndrome associated with oropharyngeal dysphagia and failure to thrive. J Pediatr 158(4):655–659

278. Portnoi MF (2009) Microduplication 22q11.2: a new chromosomal syndrome. Eur J Med Genet 52(2–3):88–93

D, Turkmen S, Cormier-Daire V, Irtihum A, Rahman N (2005) Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. Am J Hum Genet 77(2):193–204

279. Williams SR, Aldred MA, Der Kaloustian VM, Halal F, Gowans G, McLeod DR, Zondag S, Torriello HV, Magenis RE, Elsea SH (2010) Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. Am J Hum Genet 87(2):219–228

280. van Bon BW, Mefford HC, Menten B, Koolen DA, Sharp AJ, Nillesen WM, Innis JW, de Ravel TJ, Mercer CL, Fichera M, Stewart H, Connell LE, Ounap K, Lachlan K, Castle B, Van der Aa N, van Ravenswaaij C, Nobrega MA, Serra-Julhe C, Simonic L, de Leeuw N, Piundri R, Bongers EM, Baker C, Finnemore P, Huang S, Maloney VK, Crolla JA, van Kalmthout M, Elia M, Vanweweler G, Fryns JP, Janssens S, Foulds N, Reitano S, Smith K, Parkel S, Loeyes B, Woods CG, Oostra A, Speleman F, Pereira AC, Kurg A, Willatt L, Knight SJ, Vermeesch JR, Romano C, Barber JC, Mortier G, Perez-Jurado LA, Kooy F, Brunner HG, Eichler EE, Kleefstra T, de Vries BB (2009) Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome. J Med Genet 46(8):511–523

281. Thiendonk B, Bena F, Breekpot J, Philip N, Menten B, Van EH, Scalais E, Salamone JM, Fong CT, Kussmann JL, Grange JM Jr, Gorski JL, Zahir F, Yong SL, Morris MM, Gimelli S, Fryns JP, Mortier G, Friedman JM, Villard L, Bottani A, Vermeesch JR, Cheung SW, Devriendt K (2010) Duplications of the critical Rubinstein-Taybi deletion region on chromosome 16p13.3 cause a novel recognisable syndrome. J Med Genet 47(3):155–161

282. Nagamani SC, Erez A, Bader P, Lalani SR, Scott DA, Scaglia F, Plon SE, Tsai CH, Reimischel T, Roeder ER, Malphrus AD, Eng PA, Hixson PM, Kang SH, Stankiewicz P, Patel A, Cheung SW (2011) Phenotypic manifestations of copy number variation in chromosome 16p13.11. Eur J Hum Genet 19(3):280–286

283. Potocki L, Bi W, Treadwell-Deering D, Carvalho CM, Eifert A, Friedman EM, Glade D, Krull K, Lee JA, Lewis RA, Mendoza-Londono R, Robbins-Furman P, Shaw C, Shi X, Weissenberger G, Withers M, Yatsenko SA, Zackai EH, Stankiewicz P, Lupski JR (2007) Characterization of Potocki–Lupski syndrome [dup(17)(p11.2p11.2)] and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. Am J Hum Genet 80(4):633–649

284. Soler-Alfonso C, Motili KJ, Turk CL, Robbins-Furman P, Friedman EM, Zhang F, Lupski JR, Fraley JK, Potocki L (2011) Potocki–Lupski syndrome: a microduplication syndrome associated with oropharyngeal dysphagia and failure to thrive. J Pediatr 158(4):655–659

285. Portnoi MF (2009) Microduplication 22q11.2: a new chromosomal syndrome. Eur J Med Genet 52(2–3):88–93
286. Bi W, Ohyama T, Nakamura H, Yan J, Visvanathan J, Justice MJ, Lupski JR (2005) Inactivation of Rai1 in mice recapitulates phenotypes observed in chromosome engineered mouse models for Smith–Magenis syndrome. Hum Mol Genet 14(8):983–995

287. Hirotsune S, Fleck MW, Gambello MJ, Bix GJ, Chen A, Clark GD, Ledbetter DH, McBain CJ, Wynshaw-Boris A (1998) Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality. Nat Genet 19(4):333–339

288. Reiner O, Carrozzo R, Shen Y, Wehnert M, Faustinella F, Dobyns WB, Caskey CT, Ledbetter DH (1993) Isolation of a Miller–Dieker lissencephaly gene containing G protein beta-subunit-like repeats. Nature 364(6439):717–721